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Specialist paediatric palliative care for  
children and young people with cancer:  
A mixed-methods systematic review
Johanna Taylor1,2 , Alison Booth1,2 , Bryony Beresford2,3,  
Bob Phillips2,4, Kath Wright4 and Lorna Fraser1,2
Abstract
Background: Specialist paediatric palliative care services are promoted as an important component of palliative care provision, but 
there is uncertainty about their role for children with cancer.
Aim: To examine the impact of specialist paediatric palliative care for children and young people with cancer and explore factors 
affecting access.
Design: A mixed-methods systematic review and narrative synthesis (PROSPERO Registration No. CRD42017064874).
Data sources: Database (CINAHL, Cochrane Database of Systematic Reviews, Embase, MEDLINE, PsycINFO) searches (2000–2019) 
identified primary studies of any design exploring the impact of and/or factors affecting access to specialist paediatric palliative care. 
Study quality was assessed using The Mixed Methods Appraisal Tool.
Results: An evidence base of mainly low- and moderate-quality studies (n = 42) shows that accessing specialist paediatric 
palliative care is associated with less intensive care at the end of life, more advance care planning and fewer in-hospital deaths. 
Current evidence cannot tell us whether these services improve children’s symptom burden or quality of life. Nine studies 
reporting provider or family views identified uncertainties about what specialist paediatric palliative care offers, concerns 
about involving a new team, association of palliative care with end of life and indecision about when to introduce palliative 
care as important barriers to access. There was evidence that children with haematological malignancies are less likely to access 
these services.
Conclusion: Current evidence suggests that children and young people with cancer receiving specialist palliative care are cared 
for differently. However, little is understood about children’s views, and research is needed to determine whether specialist input 
improves quality of life.
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What is already known about the topic?
•• Specialist paediatric palliative care is promoted as an important component of children and young adult cancer services, 
but there is uncertainty about the factors that affect access and the benefits for children who receive this specialist 
input.
•• Three reviews, which have aggregated evidence for children with all life-limiting conditions, suggest that the benefits of 
specialist palliative care include less time in hospital and improvements in quality of life and symptom management.
•• The growing number of studies investigating the role of specialist palliative care for children with cancer report mixed 
results and varying provision, and there is a need to aggregate this evidence to inform future policy and practice.
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What this paper adds?
•• Accessing specialist paediatric palliative care is associated with less intensive care at the end of life, more advance care 
planning and fewer in-hospital deaths for children and young people with cancer, but there is no robust evidence to tell 
us whether these services lead to improvements in quality of life or symptom management.
•• Children with haematological malignancies are less likely to receive specialist palliative care than children with other 
cancers.
•• Uncertainty about when to introduce palliative care services to families, what it comprises and the added value of spe-
cialist input was identified as a key barrier to access, as were perceptions that paediatric oncology teams already meet 
the palliative care needs of their patients.
Implications for practice, theory or policy
•• Evidence is still needed to determine whether specialist paediatric palliative care improves the quality of life and symp-
tom management for children and young people with cancer.
•• Exploration of why children with certain cancers are less likely to receive specialist palliative care at the end of life may 
help address this inequality in access.
•• A core outcome set study including the views of children and families would help improve future aggregation of evi-
dence in this area.
Background
Approximately 20% of children and young people diag-
nosed with cancer do not survive despite significant medi-
cal advances in recent decades.1,2 The majority of deaths 
are due to the malignancy, with some attributable to anti-
cancer treatments.3 Distress from symptoms and suffer-
ing during the end-of-life phase can be significant,4–6 
impacting on the child and their family’s quality of life.7,8 
In addition, many children and young people who die 
from cancer continue to have high-intensity treatments 
towards the end of life,9,10 with nearly half dying in the 
acute care setting,11 despite preferences from the major-
ity of children and their parents for being at home during 
the end-of-life phase.12,13
Palliative care, defined by the World Health Organization 
(WHO) as ‘the active total care of the child’s body, mind 
and spirit . . . [that] begins when illness is diagnosed, and 
continues regardless of whether or not a child receives 
treatment directed at the disease’,14 is recognised as an 
important component of children and young people’s 
cancer services.15,16 In addition, and over the last 30 years, 
specialist paediatric palliative care services for children 
and young people have been developing in many coun-
tries including the United States, Canada, United Kingdom 
and across Europe.17 The English National Health Service 
(NHS) defines specialist paediatric palliative care as ‘a 
consultant-led multi-professional specialist palliative care 
team . . . led by a medical consultant working at Paediatric 
Palliative Care Competency Level 4’.16 In practice, how-
ever, the models of providing specialist palliative care vary 
within and between countries, including, for example, 
hospital- and community-based teams which support all 
children with life-limiting conditions,18 teams embedded 
within paediatric oncology departments, joint working 
with, or hospice-led provision, and specialist nurse-led 
teams as well as services led by a paediatric palliative care 
consultant.17,19,20
Even within the developed world, the availability, 
referral and uptake of specialist palliative care among 
children and young people with cancer remains low 
and variable between and within countries and set-
tings, and it is not clear to what extent these services 
are addressing all aspects of palliative care as defined 
by WHO.17,21–25 For children with cancer, referral to pal-
liative care also often occurs late in the trajectory of 
illness, sometimes only days before death.26,27 Recent 
systematic reviews suggest that access to specialist pal-
liative care services is associated with improvements in 
quality of life, symptom control, perceived support, 
reduced time in hospital, less invasive treatment and 
greater advance care planning.19,28,29 However, these 
reviews have aggregated the results for children and 
young people across conditions, and the evidence for 
those with cancer remains unclear because of conflict-
ing results between individual studies28 and the lack of 
work exploring condition-specific factors that may 
influence access to and benefit from specialist pallia-
tive care services.30,31
A rigorous review of the evidence on the impacts of 
specialist paediatric palliative care for children and young 
people with cancer and their families is both crucial to 
informing debates within paediatric oncology regarding 
the positioning and role of these specialist services and 
for future service development. This mixed-methods sys-
tematic review synthesises the existing evidence on the 
benefits, drawbacks, facilitators and barriers associated 
with referral to and uptake of specialist paediatric pallia-
tive care for children and young people with cancer and 
their families.
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Methods
The review questions are as follows:
1. What are the reported benefits and drawbacks of 
referral to specialist paediatric palliative care for 
children and young people with cancer and their 
families?
2. What are the factors (e.g. barriers, facilitators) 
affecting referral to and uptake of specialist paedi-
atric palliative care for children and young people 
with cancer?
The protocol registration number is CRD42017064874.32
Eligibility criteria
Primary studies of any design (e.g. experimental, obser-
vational, surveys, consensus and qualitative studies) 
examining either the impact of or factors affecting 
specialist paediatric palliative care access for children 
and young people (age 0–24 years) with cancer were 
included. Studies of a mixed population were included if 
(1) the majority of the participants were children and 
young people with cancer and/or (2) data were reported 
separately.
We defined specialist paediatric palliative care as care 
provided by multidisciplinary teams or palliative care 
services which included clinicians (e.g. oncologists, pae-
diatricians, nurses) with paediatric palliative care train-
ing, or services who self-identified as providing specialist 
paediatric palliative care. We included services delivered 
in different settings (e.g. inpatient, community or home 
settings) and both liaison services (e.g. supporting the 
child’s usual care team) and services directly supporting 
children and their families. Although broad, this reflects 
the varying provision of specialist palliative care for chil-
dren within and between different countries and so ena-
bled us to synthesise the evidence about these specialist 
services.
To understand the different perspectives on referral to 
specialist palliative care services, studies that included the 
following participant groups were eligible: children and 
young people; parents (including bereaved); other family 
members and health and social care staff. No comparator 
was required.
We excluded case studies, review articles, descriptive, 
theoretical or clinical opinion articles, conference abstracts 
and articles not published in the English language. We also 
restricted the eligibility to studies conducted in high-
income countries (defined as OECD (Organisation for 
Economic Co-operation and Development)33 member 
countries) because of the very different healthcare infra-
structure and status of specialist paediatric palliative care 
in developing countries.17
Search strategy
Electronic databases (CINAHL, Cochrane Database of 
Systematic Reviews (CDSR), Embase, MEDLINE, PsycINFO) 
were searched on 27 June 2017 (from 2000, in line with 
increasing availability of specialist paediatric palliative 
care services internationally19). The search strategy con-
sisted of terms and synonyms for [malignancies] AND 
[children] AND [specialist paediatric palliative care] (see 
Supplementary Information Appendix A.) Reference 
lists of included studies and relevant literature reviews 
were checked, and backward and forward citation 
searching of included studies and PubMed-related 
articles link searches were undertaken. An update 
search in MEDLINE (which identified all the eligible 
studies in the original search) was performed on 13 
September 2019.
Study selection
Titles and abstracts were screened in Covidence,34 and 
relevant full-text articles were retrieved and indepen-
dently assessed for eligibility by two reviewers with disa-
greements resolved via a third reviewer.35 Reasons for 
exclusion at full text were recorded.
Data extraction
Data on study characteristics, methods, study focus (e.g. 
impact and/or factors affecting access) and quantitative 
outcome data were extracted into Microsoft Excel using 
a pre-piloted data extraction template. Qualitative data, 
including author-reported results, direct quotations and 
results tables, were imported into NVivo version 1136 for 
analysis.
Data extraction was carried out by one reviewer and 
checked by a second.
Critical appraisal
The Mixed Methods Appraisal Tool (MMAT)37,38 was used 
to appraise the methodological quality of all included 
studies. MMAT comprises two generic screening ques-
tions and an additional four criteria for use with specific 
study designs. Criterion assessments (e.g. Is the sample 
representative of the population under study?) are cate-
gorised ‘Yes’, ‘No’ or ‘Can’t tell’. An overall quality score 
(of 0%, 25%, 50% or 100%) based on how many study 
design specific criterion were met (those categorised as 
‘Yes’) was calculated for each study.
The quality assessment was undertaken independently 
by two reviewers and informed the synthesis methods 
and reporting of the review results, along with identifying 
needs for future research. We did not exclude studies 
based on quality assessment.
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Data synthesis
An integrative narrative synthesis was planned drawing 
on interpretative review methodology39 with thematic 
analysis as the principal method of synthesis.40 The syn-
thesis plan outlined in the protocol32 was modified follow-
ing an assessment of the potential for aggregation, 
configuration and integration of study findings. The final 
method involved separate syntheses of data reporting the 
impact of specialist paediatric palliative care and factors 
affecting access (both included quantitative and qualita-
tive data). Each comprised the following steps:
Data reduction. This involved reviewing and summaris-
ing extracted data and identifying recurring categories 
from across the studies, and distinct service types. Each 
synthesis included quantitative and qualitative data and 
all numerical and statistical findings were converted to 
descriptive summaries. For qualitative data, ‘meaning 
units’ (comprehensible segments of text which contain 
one idea or piece of information) were identified and 
named (or ‘coded’) drawing both on author-reported 
results and participant quotes to capture the full range 
of concepts or themes across the studies.41
Data display. Using the method of constant compari-
son,39 descriptive summaries of quantitative data and 
coded qualitative data were compared to ensure that 
similar data were grouped together to develop a the-
matic coding matrix consisting of descriptive themes 
and overarching categories which grouped similar 
themes together. This was performed by one reviewer 
with regular input from the wider review team for 
sense checking and validation. Data from each study 
were then synthesised into the coding matrix, retaining 
reference to the service type and critical appraisal 
score to facilitate greater interpretation. Data display 
techniques were used to illustrate the spread of 
themes across studies and specialist paediatric pallia-
tive care models, and narrative weaving describes the 
results of each synthesis.42
Results
A total of 8549 unique records were screened by title and 
abstract, 626 full-text articles were retrieved and 
reviewed, and 49 articles describing 42 studies23,43–90 were 
included in the review (see Figure 1).
Study characteristics
Of the 42 included studies, 11 examined the impact of 
specialist paediatric palliative care,44,48,57,58,62,64,66,70,73,74,88 
14 explored factors affecting access23,43,45,56,65,68,71,75,76, 
78–83,89 and 17 studies investigated both46,47,49–55,59–61,63,67, 
69,72,77,84–87,90 (see Table 1 for study characteristics). Using 
the MMAT, 25 studies were categorised as quantitative 
non-randomised, 12 as quantitative descriptive and 5 as 
qualitative studies. The majority of studies were conducted 
in the United States (n = 28). Others were in the United 
Kingdom (n = 3),23,47,76 Canada (n = 3),50,51,63,72 Germany 
(n = 3),57,73,90 France (n = 1),87 Switzerland (n = 1),79 Israel 
(n = 1)49 and two in multiple countries.65,71
Study populations
Thirty-one studies (all quantitative) examined the impact 
of and/or characteristics of children receiving specialist 
palliative care; 24 included a comparator group of chil-
dren not receiving this,23,43–51,54–64,78,86–88,90 1 compared 
children receiving late and early specialist input,52,53,84,85 
and 6 used a single-group study design.66,67,69,70,73,74 Of the 
remaining 11 studies (6 quantitative and 5 qualitative), 10 
explored the views of healthcare staff65,71,72,75–77,79–83,89 
and 1 the views of parents and young people.68
Of the 31 studies examining outcomes and/or charac-
teristics of children, the majority (n = 21) drew their sam-
ple of children and young people from a single centre. 
Several studies used the same or potentially overlapping 
samples as other included studies (see Figure 2).
In total, data for 7933 children and young people, 4289 
of whom had received specialist palliative care compared 
to 3644 who did not, were included. While the majority 
(n = 23) included children and young people with any can-
cer, eight studies concerned children and young people 
with particular diagnoses or treatments (see Table 1 for 
details).44,56,61,62,66,67,69,78 Overall, these 31 studies address 
diagnoses from infancy to young adulthood, with only 
three studies focused on young adults, which included any 
malignancy.54,58,86 Five studies included some children and 
young people with conditions other than cancer.61,67,70,73,88
Of the 11 studies exploring stakeholder views, 3 
recruited paediatric oncology staff from single hospi-
tals75,77,82,83 and 1 from multiple hospitals,79,80 1 recruited 
staff involved in providing palliative care to children with 
cancer from primary, tertiary and community settings,76 4 
recruited paediatric oncologists via professional organisa-
tions65,71,72,81 and 1 recruited parent and young person 
dyads from three hospitals.68 In total, these studies repre-
sented the views of 1133 physicians, 986 other healthcare 
professionals (mainly nurses, social workers and other staff 
working in paediatric oncology, but also in palliative care 
and other settings), 129 parents and 129 young people.
Models of delivery
We identified five broad service types from the included 
studies: hospital-based palliative care teams with referral 
triggering an initial consultation46,50–53,58,61–64,67,69,73–75,77, 
82–85,87,88 (n = 17), hospice services23,45,47,55,56,59,60,65,86 (n = 8), 
home-based services48,57,70,90 (n = 4), integrated oncology 
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services44,66 (n = 2) and an integrated oncology inpatient 
unit49 (n = 1). Three studies referred to palliative care con-
sultation only,43,54,78 and three a palliative care team,68,79,81 
although it is likely that these were all referring to hospi-
tal-based teams. Of the remaining four studies, three 
included a range of models71,72,89 and one referred to spe-
cialist paediatric palliative care explicitly but did not 
define this.76
Very few studies provided specific details about the 
team or service providing palliative care in terms of skills 
mix, role and the extent of provision. There were also 
some anomalies between studies; for example, five stud-
ies used hospice discussions or enrolment as an outcome 
of specialist palliative care,46,61,62,64,90 whereas in other 
studies hospices were defined as the source of specialist 
intervention. Not all studies investigating hospice settings 
specified the characteristics (e.g. adult vs children’s hos-
pice), and it was difficult to determine what ‘home-based 
services’ might comprise. Among the studies exploring 
stakeholder views, three offered only ‘hypothetical mod-
els’ for participants to consider68,75,76 and three focused 
primarily on views about early integration of specialist 
palliative care, which was defined as close to the time of 
diagnosis.68,75,81
Only two studies accounted for the timing of the initial 
palliative care consult/enrolment when deciding which 
children to classify as having received specialist interven-
tion; one only included children who had received special-
ist palliative care for more than 30 days63 and the second 
for more than 1 day.54 A third study, which compared early 
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Table 1. Characteristics of included studies.
Study ID and country Population and sample size Setting SPPC description Study aim Overview of relevant methods Study investigated the following:













To examine healthcare 
utilisation and palliative 
care delivery for children 
with cancer by enrolment 
in early phase clinical 
trial
Retrospective cohort study comparing 
receipt of SPPC between children 
enrolled (n = 33) and not enrolled 
(n = 92) in an early phase clinical trial




Paediatric patients (age 
1 month–19 years) who died 





including advance care 
planning, symptom 
management, family 
liaison and home care
To examine if a 
relationship existed 
between patient 
outcomes before and 
after implementation 
of SPPC
Retrospective chart review comparing 
children who received SPPC (n = 92) 
with a historical cohort (n = 22) prior 
to SPPC implementation
Hospital admissions 






Children and young people 





Hospice enrolment To assess whether race is 
associated with end-of-
life care provision
Retrospective chart review to assess 
differences in race between children 





Haematology, oncology and 
stem cell transplant patients 




oncology and stem 
cell treatment 
divisions in one 
children’s hospital
Specialty palliative 
care consultation and 
hospice enrolment
To explore the 
associations between 
demographic variables 
and end-of-life care 
characteristics
Retrospective analysis of a 
prospectively collected database to 
compare 410 patients who received 
(n = 69) and did not receive SPPC 














Paediatric and young adult 
patients with cancer enrolled 









To investigate factors 
influencing utilisation of 
SPPC in paediatric phase 
1 trial patients
Retrospective review of 
medical records to compare the 
characteristics of children who 












Register of Cancer in 




care and community 
palliative care services 
in the Yorkshire region
To determine which 
children and young 
people with cancer use 
SPPC services
Retrospective analysis linking 
YSRCCYP and hospice records to 
assess characteristics of children 
referred to SPPC (n = 179) compared 








Children (age 0–19) who died 
from cancer
n = 657
YSRCCYP Children’s hospice 
providing in-hospice 
care and community 
palliative care services 
in the Yorkshire region
To assess the impact of 
SPPC services on planned 
and emergency hospital 
admissions before death
Retrospective analysis linking 
YSRCCYP, hospice and hospital 
records to compare admissions in 
children who received (n = 182) and 
did not receive (n = 475) hospice care
Hospital admissions 
















Study ID and country Population and sample size Setting SPPC description Study aim Overview of relevant methods Study investigated the following:




Parents of children (age 0–17 









To compare symptom 
distress and quality of life 
in children receiving and 
not receiving SPPC
Survey of parents using SCCC to 
compare outcomes for children 
receiving (n = 30) and not receiving 
(n = 30) SPPC





















and terminal care unit 
(PCU) integrated with 
the PHOD
To explore the impact of 
SPPC on hospitalisation 
and exposure to 
palliative care
Retrospective analysis of hospital 
records to compare children who 
were hospitalised in the PCU (n = 337) 
with those who were not (n = 231)






Canada (two papers 
reporting different 
outcomes from the 
same data set)









Tertiary care palliative 
care team
To examine end-of-life 
care location preferences 
and experiences 
and impact of SPPC 
involvement on end-of-
life experiences
Parent and provider questionnaires 
(using SCCC) and review of child’s 
medical records to explore 
preferences and experiences and 
compare outcomes for those 
receiving (n = 42) and not receiving 
(n = 33) SPPC
Congruence between 










United States (four 
papers reporting 
different outcomes 
from the same data 
set)
Patients with a primary 
cancer diagnosis who were 
enrolled in SPPC at the time 
of death
n = 321
One large academic 
paediatric cancer 
centre
Formal palliative care 
consultation and 
follow-up provided by 
subspecialty team of 
expert palliative care 
clinicians
To explore demographic, 
end-of-life and illness 
characteristics of children 
who receive SPPC and 
how these impact on 
timing of SPPC
Retrospective cohort study comparing 
outcomes and characteristics in those 
receiving early (n = 236) and late 
(<30 days before death) SPPC (n = 85)
Location of death 














Young adults with cancer 







To examine death 
characteristics and end-
of-life care trajectories 
for young adults with 
cancer
Retrospective chart review to 
compare differences between young 
adults receiving (n = 19) and not 





DNR order and timing






Children and adolescents 





Children’s hospice To describe the variables 
influencing end-of-
life care including the 
availability of children’s 
hospice
Retrospective chart review examining 
end-of-life care patterns and impact 
of receiving (n = 31) or not receiving 
(n = 64) SPPC
Location of death
DNR order and timing









Patients who died (at 





Hospice enrolment To determine whether 
enrolment in a phase 1 
trial affects end-of-life 
care for children with 
cancer and their families
Retrospective chart review comparing 
receipt of SPPC between children 
enrolled (n = 120) and not enrolled 
(n = 157) in a phase 1 trial



















Study ID and country Population and sample size Setting SPPC description Study aim Overview of relevant methods Study investigated the following:




Young adults who died (at 







(nearly all participants 
had hospital SPPC 
involvement)
To understand the effect 
of treatments on end-
of-life experiences for 
young adults with cancer
Retrospective cohort study to 
determine the factors associated with 
inpatient death in young adults who 
died from cancer including SPPC
Location of death Diagnosis
Revon-Rivière et al.87
France
Patients aged 0–25 at the 







care units, identified 
palliative care hospital 
beds, hospital mobile 
end-of-life teams and 
inpatient services
To determine the 
patient- and hospital-
related predictors of 
high-intensity end-of-life 
care in children and 
young people with 
cancer
Retrospective cohort study involving 
multivariable regression to determine 
the predictors of high-intensity end-












Patients aged 1–21 with a 
palliative care diagnosis who 
stayed in hospital for more 
than one night





by a palliative care 
team
To estimate the impact 
of SPPC on ICU stays 
for children with 
cancer and non-cancer 
diagnoses during hospital 
admissions
Retrospective analysis involving 
multivariable regressions to 
determine the predictors for being in 










in North Rhine 
Westphalia
Specialised paediatric 
palliative home care 
services
To assess whether 
increased national 
availability of SPPC 
improves end-of-life 
outcomes
Interviews with parents (face-to-face 
or phone) to compare a historical 
cohort of children (n = 48) with 
children exposed to SPPC (n = 48) to 













Young adults (age 15–26) 






palliative care team in 
the form of a palliative 
care consultation
To characterise and 
compare illness and 
end-of-life experiences 
and compare end-of-life 
experiences by SPPC 
involvement
Exploratory retrospective analysis 
of data extracted from medical 
records to compare young adults who 










United States (two 
papers reporting 
different outcomes 
from the same data 
set)
Children with cancer or bone 
marrow transplant (at age 
0–18) who died
n = 114
The Center for 
Cancer and Blood 





To determine if ethnicity 
is associated with 
hospice enrolment in 
children with cancer and 
to determine place of 
death
Retrospective analysis of CCBD 
records and hospice records to 
explore differences in children 
enrolled (n = 95) and not enrolled 
(n = 19) in SPPC
















Study ID and country Population and sample size Setting SPPC description Study aim Overview of relevant methods Study investigated the following:




Children who underwent 
stem cell transplantation 
(SCT) and did not survive
n = 147 (118 cancer)
One children’s 




To evaluate whether 
SPPC is associated with 
differences in end-of-life 
care
Retrospective chart review comparing 
children who received SPPC (n = 37) 


























life care patterns and 
outcomes following SPPC 
implementation
Retrospective chart review comparing 
children who received SPPC (n = 57) 
with a historical cohort (n = 134) prior 
to SPPC implementation
End-of-life discussions







Children diagnosed with a 





Ontario with an SPPC 
team (n = 3)
Hospital-based 
specialist team with 
expertise in both 
paediatrics and 
palliative care
To determine which 
children with cancer 
access SPPC and examine 
the impact of SPPC on 
high-intensity end-of-life 
care
Retrospective cohort study comparing 
children who received SPPCd (n = 166), 
general palliative care (n = 100) and 





















hospital and cancer 
institute
Paediatric Advanced 
Care Team (PACT) 
consultation
To determine whether 
introduction of SPPC has 
led to changes in end-of-
life care and outcomes
Parent survey (using SCCC) and review 
of child’s medical records to compare 
end-of-life care and outcomes for 













Parents of children who died 




departments in one 
German federal state
Specialised paediatric 
palliative home care 
services
To assess whether 
changes in SPPC 
provision and SPPC 
receipt were associated 
with quality and location 
of care and death
Repeated cross-sectional cohort 
study using interviews with parents 
(using SCCC) and questionnaire of 
paediatric oncology departments to 
compare cohorts of children from 
































Study ID and country Population and sample size Setting SPPC description Study aim Overview of relevant methods Study investigated the following:






providers (physicians, nurses 
and social workers)
n = 1005




palliative care team 
early integration model
To assess paediatric 
oncology providers’ 
perceptions of the 
barriers and facilitators 
to early integration of 
SPPC
Online survey to assess agreement 
among participants about factors 
affecting SPPC early integration 











Referral to hospice 
services/care
To examine hospice 
referral patterns and 
identify barriers to 
referral
Online survey exploring comfort 
level in dealing with end-of-life 









Parents of high-riskf 
paediatric haematology–










To evaluate family 
satisfaction with SPPC 
and its decision-making 
tool
Quantitative survey of all parents to 
assess SPPC effectiveness and follow-
up interviews (open-ended questions) 
with nine (of the 20) parents, 
analysed for patterns and trends








Children and adolescents 
admitted for haematopoietic 
stem cell transplantation 
(HSCT)
n = 12 (seven cancer cases)






service provided by a 
palliative care team
To establish the 
feasibility of integrating 
palliative care early in 
the trajectory of HSCT 
and to measure care 
outcomes
A prospective study collecting 
descriptive data on uptake and 
delivery of SPPC and parent and 








Children with oncologic 







Palliative care team 
(described as a 
group of experts 
that specialise in 
treating symptoms 
and improving quality 
of life)
To examine attitudes 
towards early integration 
of palliative care among 
young people and 
parents
Separate surveys of young people 
and parents (face to face) to compare 
views about SPPC and explore 










Children and adolescents 
(age < 22) with high-riskh 





Early palliative care 
consultation
To assess the feasibility 
and acceptability of 
early palliative care 
consultation
Prospective study collecting 
descriptive data on uptake and 
delivery of SPPC and parent views 
(survey) on acceptability
Parent satisfaction Acceptability of SPPC
Postier et al.70
United States
Children (age 1–21) with life-
threatening conditions who 
received SPPC
n = 425 (200 cancer cases)
Children’s Hospitals 






To compare hospital 
resource utilisation 
before and after 
enrolment in SPPC
Retrospective analysis of electronic 
medical record data for 12 months 
before and after a child is enrolled 
for SPPC
Hospital admissions 













Study ID and country Population and sample size Setting SPPC description Study aim Overview of relevant methods Study investigated the following:











in one US state
All paediatric palliative 
care services including 
inpatient, outpatient 
and consultation
To evaluate the 
knowledge and beliefs 
of paediatric oncology 
providers regarding 
the involvement of and 
barriers to SPPC
Cross-sectional descriptive online 
survey including 30 questions to 
explore attitudes and beliefs about 
SPPC including barriers to access
 Availability and use 
of SPPC
Beliefs about SPPC




Representatives of medical 
settings providing clinical 
care to children with cancer
n = 142
Members of AAP 
SOHPM, ASPHO WG, 









To assess the current 
status of SPPC provision 
and practice for children 
with cancer
Cross-sectional online survey to 
examine the structure, processes and 
range of services offered by palliative 
care teams, triggers to consultation 
and barriers to provision
 Perceived barriers to 
SPPC referral








of ASPHO, CAMO, 
CARO and CSSO
Specialised palliative 
care (SPC) (e.g. 
hospice, consultation, 
unit, clinic)
To describe attitudes and 
referral practices to SPC
Anonymous online and postal survey 
of SPC availability and referral 
practices and attitudes, comparing 
adult and paediatric oncologists
Provider satisfaction Attitudes about when, 







Children treated by SPPC 
service prior to death
n = 51 (29 cancer cases)
Bereaved parents








To evaluate the impact of 
SPPC programme on end-
of-life experiences
Parent survey (10 items) to assess 
satisfaction with SPPC and review 
of children’s medical records to 






Children with cancer 







care programme in 
the form of a palliative 
care consultation
To examine changes in 
treatment after referral 
to SPPC
Retrospective chart review to 
examine end-of-life care patterns for 













nurses and social workers 






The study explored all 
palliative care including 
‘institutional referral 
practices’ to specialist 
services
To examine the 
understanding of and 
attitudes towards 
paediatric palliative care
Thematic analysis of five mixed focus 
groups (one per centre) exploring 
conceptual barriers to palliative care 
implementation











care team with early 
integration model 
proposed to groups)
To explore perceptions 
of and barriers and 
facilitators to early 
integration of SPPC
Constant comparative analysis of 
exploratory focus groups with nurses 
(n = 2), oncologists (n = 1) and social 
workers (n = 1)
 Barriers to early SPPC 
model




















Study ID and country Population and sample size Setting SPPC description Study aim Overview of relevant methods Study investigated the following:




Paediatric oncology staff 





oncology and solid 




To explore how 
uncertainty might 
influence palliative 
care referrals (part of 
study co-designing an 
intervention to address 
referral barriers)
Phenomenological analysis of 16 
semi-structured individual interviews 
and field notes from co-design 
workshops to conceptualise how 
uncertainty influences referrals to 
SPPC






Health and social care 
professionals with a role in 
supporting children with 
cancer
n = 40
Primary, tertiary and 
community services 
in South East 
England
The study explored all 
palliative care including 
hospices and ‘specialist 
community palliative 
services for children 
with cancer’
To examine how 
professionals viewed 
palliative care for 
children with cancer and 
to identify provision and 
future needs
Framework analysis of individual 
semi-structured interviews and group 
discussions covering palliative care 
definitions, provision and needs












To explore how 
paediatric oncology 
providers perceived the 
SPPC service and how 
these perceptions may 
influence referral
Modified grounded theory analysis 
of individual semi-structured 
interviews with oncologists, nurses, 




perception of SPPC 
service
SPPC: specialist paediatric palliative care; DNR: do-not-resuscitate; POLST: physician order for life-sustaining treatment; SCCC: Survey about Caring for Children with Cancer; ICU: intensive care unit; CPR: cardiopulmonary resuscita-
tion; POST: physician scope of treatment; APOSW: Association of Paediatric Oncology Social Workers; AAP SOHPM: American Academy of Paediatrics Section on Hospice and Palliative Medicine; ASPHO WG: American Society of 
Paediatric Haematology and Oncology Palliative Care Working Group; AAHPM SIG: American Academy of Hospice and Palliative Medicine Paediatric Palliative Care Special Interest Group; SIOP SIG: Societe Internationale D’Oncologie 
Pediatrique Palliative Care Special Interest Group; ASPHO: American Society of Paediatric Haematology/Oncology; CAMO: Canadian Association of Medical Oncologists; CARO: Canadian Association of Radiation Oncologists; CSSO: 
Canadian Society of Surgical Oncology; SCT: stem cell treatment.
aChildren were included in the SPPC group if they had received a palliative care consultation at least 1 day before death.
bOccurrence of at least one of the following: ⩾1 session of intra-hospital intravenous chemotherapy <14 days from death; ⩾1 hospitalisation in intensive care in the last 30 days of life; >1 emergency room admission in the last 
30 days of life and >1 hospitalisation in an acute care unit in the last 30 days of life.
cOccurrence of at least one of the following: intubation and/or ventilation; CPR and haemodialysis in the last 30 days of life.
dChildren were included in the SPPC group if they had received SPPC for at least 30 days before death.
eAny one of the following: intravenous chemotherapy within 14 days of death; more than one emergency department visit; more than one hospitalisation and any ICU admission within 30 days of death.
fPatients were considered high-risk if they had approached one of the following treatment changes: (1) SCT; (2) transition to end-of-life palliative care and (3) major treatment-related change.
gTranscendent comfort was conceptually defined as a state of ease and well-being influenced by the caring and actions of nursing, which lead to transcendence of the circumstances of symptom distress, functional status and quality 
of life.
hPatients were considered high-risk if they had (1) a newly diagnosed malignancy with estimated survival of less than 50%; (2) cancer requiring SCT and (3) relapsed, recurrent or progressive cancer.
i18 countries and 39 states.
jTriggers to consultation are defined as a diagnosis or prognosis predetermined to warrant consideration of an automatic referral to the palliative care subspecialty team.
Table 1. (Continued)
Taylor et al. 13
Country Study ID Seng SPPC No SPPC
Canada Kassam et al. Hospital for Sick Children Toronto, Ontario 42 33
Canada Widger et al.
e
Three children's hospitals in Ontaria 166 406
France Revon-Rivière et al. French naonal hospital database 1308 591
Germany Schmidt et al.
a
All paediatric oncology departments in North-Rhine-Westphalia 48 48
Germany Zernikow et al.
a
All paediatric oncology departments in North-Rhine-Westphalia 65 59
Germany Wolff et al.
b
St Hedwig's Hospital, Bavaria 51 0
Israel Golan et al. Edmond and Lily Safra Children's Hospital 337 231
UK Fraser et al. YSRCCYP - Yorkshire Cancer Registry 179 297
UK Fraser et al. YSRCCYP - Yorkshire Cancer Registry 182 475
US Ananth et al.
d
Boston Children's Hospital, Massachuses 104 21
US Ullrich et al. Boston Children's Hospital, Massachuses 37 110
US Wolfe et al.
a
Boston Children's Hospital, Massachuses 119 102
US Zhukovsky et al.
b
Cancer Centre, Houston, Texas 15 0
US Thienprayoon et al. Cancer Centre, Dallas, Texas 95 19
US Arland et al.
a
Children's Hospital Colarado 92 22
US Klopfenstein et al. Children's Hospital Columbus, Ohio 31 64
US Rossfeld et al. Children's Hospital Columbus, Ohio 63 90
US Friedrichsdorf et al. Children's Hospitals and Clinics of Minnesota 30 30
US Poser et al.
b
Children's Hospitals and Clinics of Minnesota 425 0
US Lafond et al.
b,f
Children's Naonal Health Systems, Washington DC 12 0
US Mark et al. Cincinna Children's Hospital Medical Centre, Cincina, Ohio 43 28
US Cuviello et al. NCI paediatric oncology phase 1 trial parcipants 23 126
US Kline et al.
b,f
Rady Children's Hospital, San Diego, California 20 0
US Brock et al. Stanford Children's Health, Stanford, California 69 341
US Baker et al. St Jude's Children's Hospital, Memphis, Tennessee 146 199
US Kaye et al.
c
St Jude's Children's Hospital, Memphis, Tennessee 321 0
US Levine et al.
d
St Jude's Children's Hospital, Memphis, Tennessee 120 157
US Snaman et al. St Jude's Children's Hospital, Memphis, Tennessee 50 19
US Vern-Gross et al.
a
St Jude's Children's Hospital, Memphis, Tennessee 57 134
US Mahmood et al.
b
University of Rochester Medical Center, New York 20 0
US Keim-Malpass et al. University of Virginia's Hospital, Virginia 19 42
TOTAL SAMPLES 4289 3644
a = Historical cohort study; b = Single group study; c = Late vs. early SPPC; d = Phase 1 clinical trial comparison; e= no SPPC group includes general pall iave care group; f=year of publicaon as study meline not specified
Abbreviaons: NCI = Naonal Cancer Instute
20151990 1995 2000 2005 2010
Figure 2. Data collection period for studies examining outcomes or characteristics of children receiving specialist paediatric 
palliative care.
and late interventions, included all children receiving spe-
cialist palliative care but defined early provision as that 
received for more than 30 days.52,53 Only two studies 
explored how the duration of specialist paediatric pallia-
tive care exposure affected outcomes.61,70
Study quality
The quality and reporting of studies varied greatly among 
the 37 quantitative studies, with scores ranging from 0% 
to 100% (see Table 2).
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There were concerns about the representativeness 
of samples in 14 of the quantitative studies, due to the 
single-site design of many studies, long study period 
and inappropriate participant selection or recruitment 
methods.44,46,48–51,54,57,61,62,64,70,72,86,89 Assessment of rep-
resentativeness was not possible in another seven stud-
ies because of poor reporting.66,68,73,78,81,89,90 In eight 
studies, there were concerns about the comparability of 
groups (e.g. use of historical cohorts, different partici-
pant characteristics), which were not accounted for in 
the analysis.44,50,51,54,55,57,58,62,90
Although inappropriate measures were identified in 
only three studies,50,51,56,66 wider concerns about meas-
urement were evident across studies. These included how 
receipt of specialist palliative care was determined (e.g. 
from day of initial palliative care consultation); whether 
outcomes could be attributed to specialist provision or 
care from the primary oncology team; potential recall 
problems in studies using bereaved parent-reported out-
comes and failure to take account of the chronology of 
variables. For example, having a do-not-resuscitate (DNR) 
order was a predictor of specialist palliative care in some 
studies46,59,60 and an outcome in others.54,58 Determining 
the extent of these limitations was hindered by poor 
reporting of study methods.
The five qualitative studies75–77,79,83 used appropriate 
methods for sampling, data collection and analysis. 
However, there were limitations to the transferability of 
findings due to the single-site design in three stud-
ies,75–77,83 and for the third, the time period elapsed since 
the study was conducted (published in 2001 when spe-
cialist paediatric palliative care for children with cancer 
was at an early stage of development).76
The impact of specialist paediatric palliative 
care
A total of 17 distinct outcome domains were identified 
and these were categorised under one of six overarching 
categories: advance care planning (n = 9 studies), end-of-
life care provision (n = 16), location of death (n = 18), 
child’s quality of life (n = 6), family support (n = 3) and ser-
vice satisfaction (n = 7). The synthesis of results by cate-
gory and outcome domain is summarised below and in 
detail in Table 3.
Advance care planning
The outcome domains were of end of life discussions and 
decisions about attempting resuscitation (DNR orders), 
and the timing of these. Provision of specialist palliative 
care was found to be associated with an increased likeli-
hood of end-of-life discussions being documented in all 
six studies that measured this,50,54,61,62,64,74 with evidence 
from two studies that these occurred earlier in the child’s 
illness in those receiving specialist palliative care.61,64 Six 
studies found that DNR orders occurred earlier in care tra-
jectories in those receiving specialist palliative 
care.46,54,55,58,62,64 However, the evidence about whether a 
DNR order was more likely was mixed.46,54,55,61,62,64
End-of-life care provision
There was evidence from the seven studies which 
measured treatment intensity54,58,61,63,64,87,88 that chil-
dren who received specialist paediatric palliative care 
were less likely to receive high-intensity treatments 
and to spend less time in an intensive care unit (ICU) 
during the end-of-life phase, compared to children who 
did not receive this. There was also evidence from the 
five studies which assessed hospital admissions (either 
the duration of stay or the number of admissions) that 
children who received specialist palliative care spent 
less time in the hospital than those who did 
not.44,47,55,70,90 Only one study compared the types of 
admission; here specialist palliative care was only 
found to decrease the number of planned admissions.47 
Two studies examined the cost of care, also focusing on 
hospital admissions, but did not find any significant dif-
ferences between before and after specialist input,70 or 
between those who received specialist palliative care 
and those who did not.54
There was no evidence to suggest that hospice care, 
either enrolment or utilisation, changed as a result of spe-
cialist involvement from the four studies that explored 
this.46,61,62,90 Outpatient care,90 home-based care57 and 
preferred location of care51 were each assessed by a single 
study so no conclusions can be drawn about these.
Location of death
A total of 17 studies examined differences in location of 
death between children receiving and not receiving spe-
cialist palliative care. A consistent finding across studies 
was that children who received this were less likely to die 
in ICU.49,52,54,57,58,61,64,84 However, studies varied in whether 
or not they found differences in the proportion of home or 
hospital deaths.46,48,57,59,60,62,64,73,90 For example, the study 
comparing early and late involvement of a hospital team 
found that ‘late access’ children were nearly five times 
more likely to die in ICU than at home or in a hospice, but 
observed no differences in terms of non-ICU hospital ver-
sus home/hospice deaths.52 However, they did find lower 
odds of hospital deaths when comparing hospice and no 
hospice involvement.84 Just four studies investigated the 
impact of specialist palliative care on whether children 
died in their/families preferred location of death,48,51,57,90 
three of which found that congruence between preferred 










Table 2. Critical appraisal summary for included studies.
Quantitative non-randomised studies
Study ID Overall 
score (%)a





















Are the participants 
comparable, or do 
researchers take into 
account the difference 
between groups?





Ananth et al.43 100 Yes Yes Yes Yes Yes Yes
Arland et al.44 0 Yes Yes No Can’t tell No No
Baker et al.45 100 Yes Yes Yes Yes Yes Yes
Brock et al.46 75 Yes Yes No Yes Yes Yes
Cuviello et al.78 0 Yes Yes Can’t tell Can’t tell Can’t tell Can’t tell
Fraser et al.23 100 Yes Yes Yes Yes Yes Yes
Fraser et al.47 100 Yes Yes Yes Yes Yes Yes
Friedrichsdorf et al.48 50 Yes Yes No Yes Yes No
Golan et al.49 75 Yes Yes No Yes Yes Yes
Kassam et al.50 0 Yes Yes No No No No
Kaye et al.84 100 Yes Yes Yes Yes Yes Yes
Keim-Malpass et al.54 50 Yes Yes No No Yes Yes
Klopfenstein et al.55 50 No Yes Yes Can’t tell No Yes
Mark et al.86 25 Yes Yes No Can’t tell Can’t tell Yes
Levine et al.56 75 Yes Yes Yes No Yes Yes
Revon-Rivière et al.87 75 Yes Yes Yes Yes Yes Can’t tell
Rossfeld et al.88 100 Yes Yes Yes Yes Yes Yes
Schmidt et al.57 0 Yes Yes No Can’t tell Can’t tell No
Snaman et al.58 50 Yes Yes Yes Yes Can’t tell Can’t tell
Thienprayoon et al.60 100 Yes Yes Yes Yes Yes Yes
Ullrich et al.61 50 Yes Yes No Yes Yes No
Vern-Gross et al.62 25 Yes Yes No Yes No Can’t tell
Widger et al.63 100 Yes Yes Yes Yes Yes Yes
Wolfe et al.64 25 Can’t tell Can’t tell No Can’t tell Yes Can’t tell



















Study ID Overall 
score (%)











Is the sampling 
strategy relevant to 
address the research 
question?
Is the sample 





Is there an 
acceptable response 
rate?
Dalberg et al.81 25 Yes Yes Can’t tell Can’t tell Yes No
Fowler et al.65 75 Yes Yes No Yes Yes Yes
Kline et al.66 0 Yes No Can’t tell Can’t tell No No
Lafond et al.67 100 Yes Yes Yes Yes Yes Yes
Levine et al.68 75 Yes Yes Can’t tell Yes Yes Yes
Mahmood et al.69 100 Yes Yes Yes Yes Yes Yes
Postier et al.70 0 Yes Can’t tell No No Can’t tell Can’t tell
Spruit et al.89 50 Yes Yes Yes Can’t tell Yes No
Weaver et al.71 75 Yes Yes Yes Yes Yes Can’t tell
Wentlandt et al.72 50 Yes Yes Yes No Can’t tell Yes
Wolff et al.73 0 Can’t tell Can’t tell Can’t tell Can’t tell Can’t tell No
Zhukovsky et al.74 75 Yes Yes Yes Yes Can’t tell Yes
Qualitative studies
Study ID Overall 
score (%)











Are the sources of 
qualitative data 
relevant to address 
the research question?
Is the process for 
analysing qualitative 
data relevant to address 
the research question?
Is appropriate 
consideration given to 
how findings relate to 




to how findings 
relate to researchers’ 
influence?
De Clercq et al.79 100 Yes Yes Yes Yes Yes Yes
Dalberg et al.75 100 Yes Yes Yes Yes Yes Yes
Hill et al.83 75 Yes Yes Yes Yes Yes No
Spencer and Battye76 75 Yes Yes Yes Yes Yes No
Szymczak et al.77 100 Yes Yes Yes Yes Yes Yes










Table 3. Impact of specialist paediatric palliative care by outcome domain.
Outcome domain SPPC model Study ID Outcome descriptor Summary findinga Study 
design
Quality (%)
Advance care planning (n = 9 studies)
DNR order (n = 7 
studies)
Hospice service Klopfenstein et al.55 DNR order in place More likely in the SPPC group (no p value) and after SPPC implemented (p < 0.05) Qn-NR 50
Hospital team Vern-Gross et al.62 DNR order in place Higher rate in the SPPC vs non-SPPC group (p < 0.001) Qn-NRb 25
Hospital team Brock et al.46 DNR order/POLST in place No significant difference between the SPPC and non-SPPC groups (p = 0.09) Qn-NR 75
Hospital team Ullrich et al.61 DNR order in place Higher rate in the SPPC vs non-SPPC group (p = 0.002), but no association between 
DNR order and SPPC durationc (p = 1.0)
Qn-NR 50
Hospital team Wolfe et al.64 DNR order in place No significant difference between the SPPC and non-SPPC groups (p = 0.051) Qn-NRb 25
PC consult Keim-Malpass et al.54 DNR order in place No significant difference between the SPPC and non-SPPC groups (p = 0.876) Qn-NR 50
Hospice service Klopfenstein et al.55 Time order in effect In effect for longer in the SPPC vs non-SPPC group (p < 0.001) Qn-NR 50
Hospital team Vern-Gross et al.62 Time order in effect prior to death In effect for longer in the SPPC vs non-SPPC group (p = 0.001) Qn-NRb 25
Hospital team Wolfe et al.64 Time order in effect prior to death In effect for longer in the SPPC (18 days) vs non-SPPC (12 days) group (p = 0.031) Qn-NRb 25
Hospital team Brock et al.46 Time order in effect prior to death In effect for longer in the SPPC vs non-SPPC group (p = 0.05) Qn-NR 75
Hospital team Snaman et al.58 Time order in effect prior to death In effect for longer in the SPPC vs non-SPPC group (p = 0.008) Qn-NR 50
PC consult Keim-Malpass et al.54 Time order in effect prior to death In effect for longer in the SPPC vs non-SPPC group (p = 0.001) Qn-NR 50
EOL discussions 
(n = 6 studies)
Hospital team Kassam et al.50 Numbers (11 EOL care elements) Five elements more likely in the SPPC group (p < 0.05); no difference for the other 
six (p ⩾ 0.05)
Qn-NR 0
PC consult Keim-Malpass et al.54 Numbers (documented family 
meeting)
More meetings held in the SPPC (95%) vs non-SPPC group (p = 0.036) Qn-NR 50
Hospital team Ullrich et al.61 Numbers (prognosis, DNR status) More discussions in the SPPC group (prognosis: 97% vs 83%, p = 0.04; resuscitation: 
88% vs 58%, p = 0.002), but no association with SPPC durationc (p = 0.5, p = 1.0)
Qn-NR 50
Hospital team Wolfe et al.64 Numbers (prognosis, hospice, DNR) More hospice discussions in the SPPC (76% vs 54%, p < 0.001) group, others no 
difference
Qn-NRb 25
Hospital team Vern-Gross et al.62 Numbers (total number per patient) More in the SPPC (median = 12) vs non-SPPC (median = 3) group (p < 0.001) Qn-NRb 25
Hospital team Vern-Gross et al.62 Numbers (total pre- vs post-SPPC) No significant difference in total number before vs after SPPC receipt (0.386) Qn-NRb 25
Hospital team Ullrich et al.61 Timing (days before death) Earlier in the SPPC group (prognosis: 8 vs 2 days, p < 0.001; resuscitation: 7 vs 
2 days, p < 0.001)
Qn-NR 50
Hospital team Wolfe et al.64 Timing (days before death) Earlier hospice discussions in the SPPC (52 vs 28 days, p = 0.002) group, others no 
difference
Qn-NRb 25
Hospital team Zhukovsky et al.74 Treatment recommendations by 
SPPC team
SPPC ‘resulted in multiple treatment recommendations for . . . end of life care 
planning’
Qn-D 75
EOL care provision (n = 16 studies)
Home-based care 
(n = 1 study)
Home-based service Schmidt et al.57 Home-based care received by families Higher in the SPPC (65%) vs non-SPPC (35%) group (p = 0.007) Qn-NRb 0
Hospital admissions 
(n = 6 studies)
Home-based service Postier et al.70 Admission rates (total number 
12 months pre- vs post-SPPC) by 
duration of SPPC exposure
Children with the least SPPC exposure (under 3 months) experienced a significant 
decrease in the total number of admissions, whereas those with the highest 
SPPC exposure (12 months or more) experienced a significant increase. Others 
experienced no significant difference (p values missing)
Qn-D 0
Home-based service Zernikow et al.90 Admission to hospital during the last 
month of life
Fewer children in the SPPC group stayed in hospital (40%) compared to those in 
the non-SPPC group (84%) (p < 0.0001)
Qn-NR 25
Hospice service Fraser et al.47 Admission rates (emergency, planned 
and overall)
Lower planned admission rates in children referred to SPPC (IRR = 0.60, CI = 0.43–
0.85, p = 0.004); no significant effect on overall or emergency admission rates
Qn-NR 100
Integrated service Arland et al.44 Admission rates (number of 
patients admitted, total number of 
admissions)
Fewer patients in the SPPC (29%) vs non-SPPC (54%) group admitted to hospital 




















Outcome domain SPPC model Study ID Outcome descriptor Summary findinga Study 
design
Quality (%)
PC consult Keim-Malpass et al.54 Cost of hospital stays No significant difference in cost between the SPPC and non-SPPC groups (p = 0.925) Qn-NR 50
Home-based service Postier et al.70 Cost of hospital admissions 
12 months pre- vs post-SPPC
No significant difference in total hospital charges pre- and post-SPPC initiation (p 
value missing)
Qn-D 0
Home-based service Postier et al.70 Length of stay (mean days) No significant difference in the length of stay pre- and post-SPPC initiation (p value 
missing)
Qn-D 0
Hospice service Klopfenstein et al.55 Length of last hospital stay (days) Shorter stay in the SPPC vs non-SPPC group (p value missing) Qn-NR 50
Integrated service Arland et al.44 Length of stay (mean days, total days) Shorter average length of stay in the SPPC (3.03 days) vs non-SPPC (4.05 days) 
group and fewer admission days in SPPC vs non-SPPC patients (1.25 vs 3.68) (p 
values missing)
Qn-NRb 0
Hospice care (n = 5 
studies)
Home-based service Zernikow et al.90 Hospice utilisation (time spent in 
hospice)
No significant difference between the SPPC and non-SPPC groups (p ⩾ 0.723) Qn-NR 25
Hospital team Brock et al.46 Hospice enrolment numbers No significant difference between the SPPC and non-SPPC groups (p = 0.66) Qn-NR 75
Hospital team Ullrich et al.61 Hospice enrolment numbers No significant difference between the SPPC and non-SPPC groups (p = 0.6) although 
children who received SPPC for longer (⩾1 month)c were more likely to receive 
hospice care (41% vs 5%) (p = 0.01)
Qn-NR 50
Hospital team Vern-Gross et al.62 Hospice enrolment numbers Higher in the SPPC (71%) vs non-SPPC (46%) group (p = 0.002) Qn-NRb 25
Hospital team Vern-Gross et al.62 Hospice enrolment timing (days to 
death)
No significant difference between the SPPC and non-SPPC groups (p = 0.277) Qn-NRb 25
Hospital team Brock et al.46 Hospice utilisation (time spent at 
hospice)
No significant difference between the SPPC and non-SPPC groups (p = 0.95) Qn-NR 75
Outpatient care 
(n = 1 study)
Home-based service Zernikow et al.90 Outpatient treatment or daycare No significant differences between the SPPC and non-SPPC groups (both p ⩾ 0.723) Qn-NR 25
Preferred location 
of care (n = 1 study)
Hospital team Kassam et al.51 Congruence between preferred and 
actual location of EOL care
Congruence not associated with SPPC involvement (p = 0.07)d Qn-NR 0
Treatment intensity 
(n = 7 studies)
Hospital team Revon-Rivière et al.87 Acute care unit (short-term medical 
treatment for acute illnesses) 
admission in the last 30 days of life
No significant difference between the SPPC and non-SPPC groups (multivariate 
analysis, p = 0.058, significance in univariate analysis not reported but p < 0.2)
Qn-NR 75
Hospital team Snaman et al.58 CPR attempts (in LMOL) No significant difference between the SPPC and non-SPPC groups (p = 0.203) Qn-NR 50
Hospital team Ullrich et al.61 CPR attempts Fewer in the SPPC (3%) vs non-SPPC (20%) group (p = 0.03), but no association 
between CPR attempts and SPPC durationc (p = 1.0)
Qn-NR 50
PC consult Keim-Malpass et al.54 CPR attempts No significant difference between the SPPC and non-SPPC groups (p = 0.759) Qn-NR 50
Hospital team Snaman et al.58 Dialysis (in LMOL) No significant difference between the SPPC and non-SPPC groups (p = 0.232) Qn-NR 50
Hospital team Revon-Rivière et al.87 Emergency room admission in the 
last 30 days of life
No significant difference between the SPPC and non-SPPC groups (p > 0.2) Qn-NR 75
Hospital team Revon-Rivière et al.87 High-intensity end-of-life (HI-EOL) 
care (composite – see Table 1)
Odds of receiving HI-EOL care were lower in the SPPC (51%) vs non-SPPC (83%) 
group (multivariate analysis, OR = 0.31, p < 0.001). Early (>1 month before death) 
vs late (within the month of death) SPPC was also associated with less HI-EOL care 
(p < 0.001)
Qn-NR 75
Hospital team Revon-Rivière et al.87 High-intensity end-of-life care – most 
invasive (MI-EOL) (composite – see 
Table 1)
Odds of receiving MI-EOL care were lower in the SPPC vs non-SPPC group 
(multivariate analysis, OR = 0.14, p < 0.001)
Qn-NR 75
Hospital team Widger et al.63 HIT (composite – see Table 1) Odds of receiving HIT were lower in the SPPC vs non-SPPC group (OR = 0.2, 
p < 0.001)
Qn-NR 100
PC consult Keim-Malpass et al.54 ICU length of stay No significant difference between the SPPC and non-SPPC groups (p = 0.979) Qn-NR 50
PC consult Keim-Malpass et al.54 ICU stay (all patients died as 
inpatients)











Outcome domain SPPC model Study ID Outcome descriptor Summary findinga Study 
design
Quality (%)
Hospital team Revon-Rivière et al.87 ICU stay in the last 30 days of life Odds of ICU stay lower in the SPPC vs non-SPPC group (multivariate analysis, 
OR = 0.16, p < 0.001)
Qn-NR 75
Hospital team Rossfeld et al.88 ICU stay within a hospital admission Receipt of SPPC within 1 day of hospital admission was associated with 79% lower 
odds of being in the ICU (OR = 0.21, p < 0.001). If SPPC was initiated further into a 
hospital stay, the association weakened (e.g. on day 7 the odds changed to 74%)
Qn-NR 100
Hospital team Widger et al.63 ICU stay within 30 days of death Odds of ICU admission lower in the SPPC vs non-SPPC group (OR = 0.2, p < 0.001) Qn-NR 50
Hospital team Ullrich et al.61 Intubations in the last 24 h Fewer in the SPPC (42%) vs non-SPPC (66%) group (p = 0.02), but no association 
between intubations and SPPC durationc (p = 0.9)
Qn-NR 50
Hospital team Wolfe et al.64 Intubations in last 24 h No significant difference between the SPPC and non-SPPC groups (p = 0.303) Qn-NRb 25
Hospital team Snaman et al.58 Invasive medical procedures (LMOL) Fewer received in the SPPC (median = 1) vs non-SPPC (median = 3) group 
(p = 0.009)
Qn-NR 50
Hospital team Snaman et al.58 Mechanical ventilation (LMOL) Fewer mechanical ventilations in the SPPC group (34% vs 63%, p = 0.028) Qn-NR 50
Hospital team Widger et al.63 Mechanical ventilation within 14 days 
of death
Odds of ventilation lower in the SPPC vs non-SPPC group (OR = 0.2, p < 0.001) Qn-NR 100
Hospital team Snaman et al.58 Received benzodiazepines or opioids 
(LMOL)
No significant difference between the SPPC and non-SPPC groups (p = 0.207, 
p = 1.00)
Qn-NR 50
Hospital team Revon-Rivière et al.87 Received chemotherapy <14 days 
from death
No significant difference between the SPPC and non-SPPC groups (multivariate 
analysis, p = 0.183, significance in univariate analysis not reported but p < 0.2)
Qn-NR 75
Hospital team Snaman et al.58 Received chemotherapy (LMOL) No significant difference between the SPPC and non-SPPC groups (p = 0.731) Qn-NR 50
Hospital team Wolfe et al.64 Timing of stopping cancer-directed 
treatment
No significant difference between the SPPC and non-SPPC groups (p = 0.163) Qn-NRb 25
Location of death (n = 18 studies)
Location of death 
(n = 17 studies)
Home-based service Friedrichsdorf et al.48 Home deaths More in the SPPC (93%) vs non-SPPC (20%) group (p < 0.001) Qn-NR 50
Home-based service Schmidt et al.57 Home deaths No significant difference between the SPPC vs non-SPPC groups (p value missing) Qn-NRb 0
Home-based service Zernikow et al.90 Home deaths More in the SPPC (78%) vs non-SPPC (19%) group (p < 0.005) Qn-NR 25
Hospital team Brock et al.46 Home deaths No significant difference between the SPPC and non-SPPC groups (p = 0.77) Qn-NR 75
Hospital team Wolfe et al.64 Home deaths No significant difference between the SPPC and non-SPPC groups (p value missing) Qn-NRb 25
Hospital team Wolff et al.73 Home deaths More home deaths in the SPPC (69%) vs non-SPPC (18%) group (p = 0.049) Qn-D 0
PC consult Thienprayoon et al.60 Home deaths No significant association between PC consult and home death (p = 0.61) Qn-NR 100
Hospice service Brock et al.46 Home or hospice deaths More in the SPPC (75%) vs non-SPPC (5%) group (OR = 60, p < 0.0001) Qn-NR 75
Hospice service Kaye et al.84 Home/hospice vs hospital (non-ICU) 
deaths
Lower odds (OR = 0.12) of hospital (non-ICU) death with hospice involvement 
(p < 0.001)
Qn-NR 100
Hospice service Kaye et al.84 Home/hospice vs ICU deaths Lower odds (OR = 0.02) of ICU death with hospice involvement (p < 0.0001) Qn-NR 100
Hospital team Kaye et al.84 Home/hospice vs hospital (non-ICU) 
deaths
Similar odds of dying in hospital (non-ICU) for the early SPPCe and late SPPC groups 
(p = 0.855)
Qn-NR 100
Hospital team Kaye et al.84 Home/hospice vs ICU deaths Higher odds (OR = 4.7) of ICU death in the late SPPCe vs early SPPC group 
(p < 0.0001)
Qn-NR 100
Hospital team Ullrich et al.61 Home vs hospital (non-ICU) vs ICU 
deaths; home vs hospital (all)
No significant difference in numbers of home, hospital or ICU deaths (p = 0.06) or 
between numbers who died at home or hospital (p = 0.5), and no association with 
SPPC durationc (p = 0.1, p = 0.08)
Qn-NR 50
Hospital team Vern-Gross et al.62 Home vs home hospital vs inpatient 
vs other vs unknown
No significant differences between the SPPC and non-SPPC groups (p = 0.06) and 




















Outcome domain SPPC model Study ID Outcome descriptor Summary findinga Study 
design
Quality (%)
Hospice service Thienprayoon et al.59 Home vs hospital (non-ICU) vs ICU 
vs other
More home deaths with SPPC (61% vs 0%); fewer hospital (15% vs 47%) and ICU 
(5% vs 47%) deaths (p < 0.001)
Qn-NR 100
Integrated unit Golan et al.49 Home vs hospital (non-ICU) vs ICU 
deaths
Declines in hospital (p < 0.001) and home (p = 0.003)f deaths after opening due to 
children dying in a new unit, although no change in ICU deaths
Qn-NR 75
Hospice service Klopfenstein et al.55 Hospital deaths Fewer hospital deaths in the SPPC (19%) vs non-SPPC (78%) group (p < 0.0001)g Qn-NR 50
Hospice service Mark et al.86 Hospital deaths Odds of hospital death lower in the SPPC vs non-SPPC group (remained significant 
in multivariate analysis, OR = 58.8, p = 0.0011)
Qn-NR 25
Hospital team Widger et al.63 Hospital deaths Odds of in-hospital death lower in the SPPC vs non-SPPC group (OR = 0.2, 
p < 0.001)
Qn-NR 100
Integrated service Arland et al.44 Hospital deaths No significant difference between the SPPC and non-SPPC groups (χ2 = 0.642, 
df = 1, p < 0.05)
Qn-NRb 0
Hospital team Wolfe et al.64 ICU/external hospital (of hospital 
deaths)
Fewer in the SPPC (22%) vs non-SPPC (38%) group (p = 0.024) Qn-NRb 25
Hospital team Snaman et al.58 ICU deaths Fewer ICU deaths in the SPPC (38%) vs non-SPPC (68%) group (p = 0.024) Qn-NR 50
Integrated unit Golan et al.49 ICU deaths Of all ICU deaths, 8% had used SPPC compared to 92% who had not (p < 0.001) Qn-NR 75
Home-based service Schmidt et al.57 ICU deaths (as the proportion of 
hospital deaths)
No significant difference between the SPPC and non-SPPC groups (p = 0.107) Qn-NRb 0
Hospital team Ullrich et al.61 ICU deaths (as the proportion of 
hospital deaths)
Fewer in the SPPC (58%) vs non-SPPC (80%) group (p = 0.03), but no association 
between ICU deaths and SPPC durationc (p = 0.5)
Qn-NR 50
PC consult Keim-Malpass et al.54 ICU deaths (as the proportion of 
hospital deaths)




of death (n = 4 
studies)
Home-based service Friedrichsdorf et al.48 Proportion of parents who were able 
to plan the location of death
No significant difference between the SPPC and non-SPPC groups (p = 0.08) Qn-NR 50
Home-based service Friedrichsdorf et al.48 Proportion of children who died at 
the planned location
No significant difference between the SPPC and non-SPPC groups (p = 0.14) Qn-NR 50
Home-based service Friedrichsdorf et al.48 Congruence between home as a 
preferred and actual location of 
death
Congruence increased with SPPC involvement: the vast majority of children who 
died at home were in the SPPC group as per their wishes (93%) compared with the 
non-SPPC group (20%) (p < 0.001)
Qn-NR 50
Home-based service Schmidt et al.57 Preferred vs actual location of death No significant difference in the actual vs preferred location between groups (p 
value missing)
Qn-NRb 0
Home-based service Zernikow et al.90 Proportion of parents who were able 
to plan the location of death
Families who received SPPC were more likely to plan the location of death than 
those who did not receive SPPC (75% vs 48%, p = 0.003)
Qn-NR 25
Home-based service Zernikow et al.90 Proportion of children who died at 
the planned location
Congruence in the actual vs planned place of death increased with SPPC 
involvement (92% of children died in the planned place vs 64%, p = 0.001)
Qn-NR 25
Hospital team Kassam et al.51 Congruence between the preferred 
and the actual location of death
Congruence in the preferred vs actual location of death increased with SPPC 
involvement (p = 0.03) (remained significant in the multivariate analysis)
Qn-NR 0
Child’s quality of life (n = 8 studies)
Comfort (n = 1 
study)
Hospital team Lafond et al.67 Transcendent comfort (child report) No significant change in comfort over time (p value missing) Qn-D 100
Hospital team Lafond et al.67 Transcendent comfort (parent report) Comfort significantly increased from time of treatment to discharge (p = 0.008); in 
addition, all parents reported that SPPC was very helpful (80%) or helpful (20%) in 












Outcome domain SPPC model Study ID Outcome descriptor Summary findinga Study 
design
Quality (%)
Quality of life (n = 2 
studies)
Home-based service Friedrichsdorf et al.48 Amount of fun (parent report) More fun in the SPPC vs non-SPPC group (p = 0.03) Qn-NR 50
Home-based service Friedrichsdorf et al.48 Felt peaceful (parent report) No significant difference between the SPPC and non-SPPC groups (p = 0.63) Qn-NR 50
Home-based service Friedrichsdorf et al.48 How often afraid (parent report) No significant difference between the SPPC and non-SPPC groups (p = 0.15) Qn-NR 50
Home-based service Friedrichsdorf et al.48 Event adding meaning (parent report) More events in the SPPC vs non-SPPC group (p = 0.02) Qn-NR 50
Integrated service Kline et al.66 Parents asked if SPPC improved 
child’s QoL
70% strongly agreed that SPPC improved child’s quality of life Qn-D 0
Symptoms (n = 5 
studies)
Home-based service Friedrichsdorf et al.48 Suffering from symptoms (parent 
report)h
More parents reporting ‘a great deal/lot of’ suffering from fatigue in the SPPC 
(93%) vs non-SPPC (63%) group (p = 0.007); no difference in suffering across other 
12 symptoms measuredh
Qn-NR 50
Home-based service Schmidt et al.57 Suffering from symptoms (parent 
report)i
More parents reporting ‘a great deal/lot of’ suffering from fatigue in the SPPC 
(50%) vs non-SPPC (25%) group (p = 0.01); no difference in suffering across other 
six symptoms measuredi
Qn-NRb 0
Home-based service Zernikow et al.90 Suffering from symptoms (parent 
report)i
The proportion of parents reporting symptoms as distressing for their child did not 
differ between the three cohorts (years 2000, 2005 and 2010, all p ⩾ 0.029)
Qn-NRb 25
Hospital team Wolfe et al.64 Suffering from symptoms (parent 
report)j
Fewer parents reporting ‘a great deal/lot’ of suffering of pain and dyspnoea in 
the SPPC vs non-SPPC group (pain 47% vs 66%, p = 0.018; dyspnoea 37% vs 58%, 
p = 0.020). For the other two, there were no significant differencesj
Qn-NRb 25
Home-based service Friedrichsdorf et al.48 Symptom prevalence (parent report)h More constipation in the SPPC (70%) vs non-SPPC (36%) group (p = 0.01); no 
difference across the other 12 symptoms measuredh
Qn-NR 50
Home-based service Schmidt et al.57 Symptom prevalence (parent report)i More nausea in the SPPC (65%) vs non-SPPC (42%) group (p = 0.024); no difference 
across other six symptoms measuredi
Qn-NRb 0
Home-based service Zernikow et al.90 Symptom prevalence (parent report)i The rate of symptom occurrence during the EOL period did not differ between the 
three cohorts (years 2000, 2005 and 2010, all p ⩾ 0.082)
Qn-NRb 25
Hospital team Snaman et al.58 Symptom prevalence (median 
documented in medical record)
No significant difference in the number of total documented symptoms (p = 0.49), 
or physical (0.78), psychosocial (0.12) or refractory (for which interventions had 
not worked) (0.47) symptoms
Qn-NR 50
Hospital team Wolfe et al.64 Symptom prevalence (parent report)j No significant difference in the prevalence of four symptoms measuredj Qn-NRb 25
Home-based service Schmidt et al.57 Treatment of symptoms (parent 
report)i
More anxiety treatment in the SPPC group (35.7% vs 8.7%, p = 0.035); no 
difference for the other six symptoms
Qn-NRb 0
Home-based service Zernikow et al.90 Treatment of symptoms (parent 
report)i
There was a significant increase in receiving treatment across the cohorts (years 
2000, 2005 and 2010) for constipation (p < 0.001) and anxiety (p = 0.044); no 
difference for the other five symptoms
Qn-NRb 25
Hospital team Zhukovsky et al.74 Treatment of symptoms by the SPPC 
team
SPPC ‘resulted in the detection of pain & other multiple symptoms’ (median of 
three per patient) and ‘multiple treatment recommendations for symptom control’
Qn-D 75
Home-based service Friedrichsdorf et al.48 Treatment success (parent report)h No significant difference between the SPPC and non-SPPC groups across symptoms Qn-NR 50
Home-based service Schmidt et al.57 Treatment success (parent report)i No significant difference between the SPPC and non-SPPC groups across symptoms Qn-NRb 0
Home-based service Zernikow et al.90 Treatment success (parent report)i No significant differences between the cohorts (years 2000, 2005 and 2010) 
(p ⩾ 0.242)
Qn-NRb 25




Hospital team Vern-Gross et al.62 Bereavement support provided Higher rate in the SPPC (96%) vs non-SPPC (50%) group (p < 0.0001) Qn-NRb 25




Hospital team Wolfe et al.64 Parent prepared for medical 
problems
Parents felt more prepared in the SPPC (56%) vs non-SPPC (27%) group (p < 0.001) Qn-NRb 25
Hospital team Wolfe et al.64 Parent prepared for EOL 
circumstances
Parents felt more prepared in the SPPC (49%) vs non-SPPC (25%) group (p = 0.002) Qn-NRb 25



















Outcome domain SPPC model Study ID Outcome descriptor Summary findinga Study 
design
Quality (%)
Service satisfaction (n = 7 studies)
Parent satisfaction 
(n = 5 studies)
Home-based service Zernikow et al.90 Parents rated the quality of care 
during their child’s EOL period and 
the tailoring of care to their child’s 
needs
There was a significant increase in satisfaction between earlier and later cohorts 
(2000 compared to 2005 and 2010) regarding quality of care (p < 0.001) and 
tailoring of care to child needs (p < 0.001)
Qn-NR 25
Hospital team Lafond et al.67 Six family satisfaction questions 
answered on a five-point Likert-type 
scale (1 = low, 5 = high satisfaction), 
with an overall score being calculated
‘Overall, families were very satisfied with integration of palliative care services’ 
– mean scores ranged from 4.6 to 5 across the questions, with a mean overall 
satisfaction score of 29 (out of possible 30). All parents reported at least 90% 
satisfaction with the SPPC service
Qn-D 100
Integrated service Kline et al.66 Evaluation included a series of 
structured questions asking parents 
how helpful the service was, 
treatments provided and some open-
ended questions
Overall, parents reported that the SPPC service was helpful (at least 70% of parents 
agreed or strongly agreed across the items). 85% parents agreed that the SPPC 
service covered adequate treatment options and 80% agreed that the treatment 
plan developed with the SPPC team was followed. In open-ended responses, 
parents also responded positively about the service, what it provided and who 
delivered it
Qn-D 0
Hospital team Mahmood et al.69 Brief satisfaction survey All (n = 16) reported being satisfied with the PC team service Qn-D 100
Hospital team Wolff et al.73 Satisfaction with the information 
received, medical care and PC, rated 
on a Likert-type scale (1 = very good, 
6 = unsatisfactory)
Overall satisfaction across the items was very good, with a mean rating of 1.6 
(1 = very good, 6 = unsatisfactory). There were no significant differences in 
satisfaction ratings between parents whose child died at home (which was 




Hospital team Lafond et al.67 Six provider satisfaction questions 
answered on a five-point Likert-type 
scale (1 = low, 5 = high satisfaction), 
with an overall score being calculated
Overall providers indicated satisfaction, with a mean score of 4.4. ‘Clinicians 
indicated that the PC team was helpful in managing symptoms and other stressors 
and in improving access to services for patients and families’
Qn-D 100
Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of 
SPPC service and how these may 
influence timing of referral
The SPPC service was highly regarded by oncology providers, who identified 
the following impacts: the SPPC team being able to spend time with families 
and provide emotional support and explore wider needs, expertise in pain and 
symptom management, supporting transition from hospital to home, around-the-
clock support, support for parents and siblings, and helping families to clarify goals
QL 100
All SPPC models Wentlandt et al.72 Paediatric oncologists asked about 
the quality of SPPC services in a 
survey
More than 83% of participants agreed or strongly agreed that they were satisfied 
with the quality of SPPC services
Qn-D 100
SPPC: specialist paediatric palliative care; DNR: do-not-resuscitate; Qn-NR: quantitative non-randomised; Qn-D: quantitative descriptive; POLST: physician order for life-sustaining treatment; EOL: end of life; IRR: incidence rate ratio; 
CI: confidence interval; CPR: cardiopulmonary resuscitation; LMOL: last month of life; OR: odds ratio; HIT: high-intensity treatment; ICU: intensive care unit; PC: palliative care; QL: qualitative.
aWhere results are reported as significant, this refers to statistical not clinical significance.
bHistorical cohort study.
cCompared children who received SPPC for less than a month and for at least a month.
dp value reported as 0.06 in text and 0.07 in the table.
eThis study compared early and late SPPC involvement, with late defined as <30 days before death.
fp value reported as 0.03 in text and 0.003 in the figure.
gFisher’s exact test performed on raw data reported in the paper.
hSymptoms measured: pain, poor appetite, nausea/vomiting, constipation, diarrhoea, breathing difficulty, energy loss/fatigue, sleep disturbance, sadness/depression, anxiety/nervousness, fear, bleeding episodes and seizures/con-
vulsions.
iSymptoms measured: fatigue, pain, loss of appetite, dyspnoea, anxiety, constipation and nausea.
jSymptoms measured: fatigue, pain, dyspnoea and anxiety.
Table 3. (Continued)
Taylor et al. 23
Child’s quality of life
This theme included three outcome domains: quality of 
life, comfort and symptoms. Data were primarily from 
parent-reported measures collected after a child had 
died. Two studies measured quality of life but did not use 
validated measures; one found that children receiving 
specialist paediatric palliative care had more fun and 
more events adding meaning compared to children not 
receiving this, but found no differences in how afraid or 
peaceful they felt.48 In the second, 70% of parents strongly 
agreed that these specialist services improved their child’s 
quality of life, but there was no comparator group.66 The 
study which measured comfort, also with no comparator, 
found an increase in comfort levels over time reported by 
parents but no change reported by children. This was the 
only study that used a child-reported measure.67 Although 
three studies suggested that treatment of symptoms 
increased with specialist involvement,57,74,90 there was lit-
tle evidence that the extent of symptom control/suffering 
from physical and emotional symptoms differed between 
children receiving and not receiving specialist palliative 
care. Indeed, high levels of suffering from symptoms were 
described by the four studies which assessed this.48,57,64,90
Family support
Only three studies investigated whether specialist paedi-
atric palliative care affected provision of support to family 
members, or the impact of that support. One study found 
that use of bereavement support for parents and siblings 
was more likely if a child had received specialist input.62 
Two studies found that specialist palliative care increased 
parent preparedness for the end-of-life phase of care.64,66
Service satisfaction
All seven studies (six surveys66,67,69,72,73,90 and one qualita-
tive77) assessing this reported high levels of family and 
professional satisfaction with specialist palliative care, 
with reported benefits including expertise in pain and 
symptom management, time to plan end-of-life care with 
families and meeting psychosocial and family needs. None 
of these studies included a comparator group, although 
one reported increasing parental satisfaction in line with 
increasing provision of specialist services.
Factors affecting specialist paediatric 
palliative care access
The synthesis of studies exploring factors affecting spe-
cialist paediatric palliative care access identified four 
overarching categories each containing several linked 
themes: sociodemographics (n = 14 studies), disease pro-
file (n = 22 studies), end-of-life care characteristics (n = 18 
studies) and acceptability of specialist paediatric palliative 
care (n = 17 studies). The synthesis of results by category 
and theme are summarised below and presented in detail 
in Table 4.
Sociodemographics
Multiple quantitative studies which investigated the soci-
odemographic profile of children and/or their families 
receiving and not receiving specialist palliative care con-
sistently showed that access was not associated with a 
child’s gender47,49,53,59,61,63,78 or ethnicity.45–47,49,50,53,59,61,78,85 
There was mixed evidence about whether a child’s 
age,47,49,50,53,55,61,63,78 or the socioeconomic status of their 
family (e.g. deprivation, education),47,50,59,63,71,87,89 influ-
enced access. Only one or two studies investigated 
language,46,59 rurality,55,63 religion46,59 and distance to 
treatment centre,63 so it was difficult to draw conclusions 
about these factors. Just two of the studies exploring staff 
attitudes assessed sociodemographic factors, focusing on 
lack of insurance coverage.71,89 The majority of partici-
pants in both studies did not view this as a barrier to 
referral.
Disease profile
Out of 12 studies examining type of cancer, 10 found that 
children with solid tumours were more likely to receive 
specialist palliative care than children with haematologi-
cal malignancies.46,47,49,50,53–55,59,61,63,78,86 Six studies inves-
tigated whether disease status (e.g. prognosis, relapse) 
was associated with access; no consistency was found 
across these, with some studies reporting conflicting resu
lts.46,49,50,54,55,61 In contrast, all the studies investigating 
staff-reported practices consistently identified children 
with a poor prognosis as those most likely to be refer
red.65,71,72,75,77,79,81,83,89 Staff in two studies believed that 
this could result in referrals that were too late for children 
to benefit from specialist input.71,79
Uncertainty about a child’s prognosis and about the 
benefits of introducing specialist palliative care earlier in 
the disease trajectory (e.g. around diagnosis) were identi-
fied as key barriers to a timely referral,65,71,75,77,79,81,83,89 
although non-physician professionals75,81 and families68 
were more receptive to early integration than physicians. 
Automatic referral triggers were used by the majority of 
providers in one study. However, in line with reported 
practice, most encouraged referrals for children during 
the end-of-life phase of care.71
End-of-life care characteristics
The end-of-life care provided to children was found to 
influence whether or not children received specialist pal-

















Table 4. Factors affecting access to specialist paediatric palliative care by theme.





Child’s age (n = 8 
studies)
Hospice service Klopfenstein et al.55 Median age at death Children receiving SPPC were older (12.4) than those not receiving SPPC (9.0) 
(p = 0.013)
Qn-NR 50
Hospice service Fraser et al.47 Age at diagnosis (0–4, 5–9, 10–14, 
15–19)
Fewer young adults (age 15–19) referred to SPPC compared to other groups (p value 
missing)
Qn-NR 100
Hospital team Kaye et al.84 Age at death (0–5, 6–12, 13 and 
older)
Compared to older children (13 and above), the youngest group (age 5 and younger) 
had higher odds of late (<30 days before death) vs early SPPC involvement 
(OR = 2.02, p = 0.03)
Qn-NRa 100
Hospital team Ullrich et al.61 Median age (time of SCT, age at 
death)
No significant differences between the SPPC and non-SPPC groups (p = 0.1 for both 
age variables)
Qn-NR 50
Hospital team Kassam et al.50 Mean age at death Children receiving SPPC were younger (8.8) than those not receiving SPPC (13.2) 
(p = 0.02)b
Qn-NR 0
Hospital team Widger et al.63 Age at death (0–4, 10–14, 15–18 vs 
5–9 (ref.))
Age of death not associated with SPPC involvement (p = 0.91 (age 0–4), p = 0.76 
(10–14), p = 0.75 (15–18))
Qn-NR 100
Integrated service Golan et al.49 Mean age at admission to the SPPC 
unit
Children receiving SPPC were older (10.8) than those not receiving SPPC (9.3) (p 
value missing)
Qn-NR 75
PC consult Cuviello et al.78 Age at death (<18, 18+) No significant differences between the SPPC and non-SPPC groups (p value missing) Qn-NR 0
Deprivation (n = 7 
studies)
Hospice service Fraser et al.47 Townsend score 1 (least) to 5 (most) 
deprived
No significant differences between the SPPC group and the whole sample (p value 
missing)
Qn-NR 100
Hospice service Thienprayoon et al.59 Payor status (Medicaid/private/
other)
No significant differences between the SPPC and non-SPPC groups (p = 0.76) Qn-NR 100
Hospital team Kassam et al.50 Parental income < $50,000 No significant differences between the SPPC and non-SPPC groups (p = 0.88) Qn-NR 0
Hospital team Revon-Rivière et al.87 Social disadvantage using deprivation 
index (FDep99 index)
Those living in socially disadvantaged areas had lower access to SPPC (68%) 
compared to those with no social disadvantage (74%) (p = 0.003)
Qn-NR 75
Hospital team Widger et al.63 Income quintile (Q1 lowest to Q5 
highest)
SPPC was less likely for the most deprived (compared to the least deprived: 
OR = 0.4, p = 0.01)
Qn-NR 100
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about barriers to 
involving SPPC
Lack of insurance coverage was identified as a barrier by 3% of nurses and 
physicians, and 11% of advanced practice professionals (e.g. nurse practitioners, 
physician assistants)
Qn-D 50
All SPPC models Weaver et al.71 Staff representatives of oncology 
settings were asked about barriers 
to referral (ever and most important 
barrier)
Lack of insurance coverage was identified as a barrier by 6% of staff participants and 
no one rated this as the most important barrier
Qn-D 75
Distance to treatment 
centre
Hospital team Widger et al.63 Long vs short distance (based on the 
75th percentile of all distances)
Children who lived a long distance from the treatment centre were less likely to 
receive SPPC (OR = 0.5, p < 0.001) compared to children who lived a short distance
Qn-NR 100
Education Hospital team Kassam et al.50 Parent had university education No significant differences between the SPPC and non-SPPC groups (p = 0.51) Qn-NR 0
Ethnicity/race (n = 9 
studies)
Hospice service Baker et al.45 Black, White No significant differences between the SPPC and non-SPPC groups (p = 0.64) Qn-NR 100
Hospice service Fraser et al.47 White, mixed, South Asian, Black, 
other
No significant difference between the SPPC and non-SPPC group (p value missing) Qn-NR 100
Hospice service Thienprayoon et al.59 Latino, non-Latino White, other Latinos were more likely to receive SPPC compared to non-Latino Whites 
(OR = 5.961, p value missing): 94% of Latinos vs 76% of non-Latino Whites vs 73% 
Other received SPPC (p = 0.02)
Qn-NR 100
Hospice service Brock et al.46 Race: White, Asian, Black, other; 
ethnicity: Latino, non-Latino
No significant differences between the SPPC and non-SPPC groups (p = 0.42 race, 
p = 0.60 ethnicity)
Qn-NR 75














Hospice service Kaye et al.84 Race: White, Black, other Race not associated with hospice involvement (p = 0.894) Qn-NR 100
Hospital team Brock et al.46 Race: White, Asian, Black, other; 
ethnicity: Latino, non-Latino
No significant differences between the SPPC and non-SPPC groups (p = 0.22 race, 
p = 0.49 ethnicity)
Qn-NR 75
Hospital team Kassam et al.50 Parental White race No sigifnicant difference between the SPPC and non-SPPC groups (p = 0.49) Qn-NR 0
Hospital team Kaye et al.84 Ethnicity: non-Hispanic, Hispanic/
Latino
Ethnicity not associated with the timing of SPPC involvement (early vs late) 
(p = 0.35) or days between SPPC initiation and death (p = 0.578)
Qn-NRa 100
Hospital team Kaye et al.84 Race: White, Black/African American, 
other
Race not associated with the timing of SPPC involvement (early vs late) (p = 0.73 
Black, p = 0.27 Other) or days between SPPC initiation and death (p = 0.488)
Qn-NRa 100
Hospital team Ullrich et al.61 Race: White; ethnicity: non-Hispanic No significant differences between the SPPC and non-SPPC groups (p = 0.4 race, 
p = 0.8 ethnicity)
Qn-NR 50
Integrated service Golan et al.49 Jewish, Muslim, Christian No significant differences between the SPPC and non-SPPC groups (p value missing) Qn-NR 75
PC consult Cuviello et al.78 White, Asian, Black, Hispanic, 
multiracial
No significant differences between the SPPC and non-SPPC groups (p value missing) Qn-NR 0
Gender (n = 7 studies) Hospice service Fraser et al.47 Male, female No significant difference between the SPPC and non-SPPC groups (p value missing) Qn-NR 100
Hospice service Thienprayoon et al.59 Male, female No significant difference between the SPPC and non-SPPC groups (p = 0.62) Qn-NR 100
Hospital team Kaye et al.84 Male, female Gender not associated with the timing of SPPC involvement (early vs late) (p = 0.73) Qn-NRa 100
Hospital team Ullrich et al.61 Male, female No significant difference between the SPPC and non-SPPC groups (p = 0.5) Qn-NR 50
Hospital team Widger et al.63 Male, female Gender not associated with SPPC involvement (p = 0.99) Qn-NR 100
Integrated service Golan et al.49 Male, Female No significant difference between the SPPC and non-SPPC groups (p value missing) Qn-NR 75
PC consult Cuviello et al.78 Male, female No significant differences between the SPPC and non-SPPC groups (p value missing) Qn-NR 0
Language (n = 2 studies) Hospice service Brock et al.46 English vs non-English speakers No significant difference between the SPPC and non-SPPC groups (p = 0.45) Qn-NR 75
Hospice service Thienprayoon et al.59 English/Spanish/other (primary) No significant differences between the SPPC and non-SPPC groups (p = 0.07) Qn-NR 100
Hospice service Thienprayoon et al.59 Limited English proficiency More families with limited English proficiency accessed SPPC (30% vs 5%, p = 0.02) Qn-NR 100
Hospital team Brock et al.46 English vs non-English speakers No significant difference between the SPPC and non-SPPC groups (p = 0.07) Qn-NR 75
Religion (n = 2 studies) Hospice service Brock et al.46 Christian/Catholic, no religion, other 
religion
Christian/Catholic children utilised hospice (55%) at a rate similar to those with no 
religious preference (57%), but more commonly than children with other religious 
beliefs (33%) (p = 0.03)
Qn-NR 75
Hospice service Thienprayoon et al.59 Catholic, Christian, Protestant, other No significant difference between the SPPC and non-SPPC groups (p = 0.10) Qn-NR 100
Rurality (n = 2 studies) Hospice service Klopfenstein et al.55 Rural, urban, suburban county No significant difference between the SPPC and non-SPPC groups (p value missing) Qn-NR 50
Hospital team Widger et al.63 Rural, urban Rurality not associated with SPPC involvement (p = 0.96) Qn-NR 100
Disease profile (n = 22 studies)
Cancer diagnosis (n = 12 
studies)
Hospice service Brock et al.46 Solid, brain, haematologic, 
leukaemia/lymphoma
Children with brain or solid tumours received SPPC more frequently than those 
with other cancers (p < 0.0001). No children with haematologic malignancies were 
enrolled in SPPC
Qn-NR 75
Hospice service Fraser et al.47 ICCC diagnostic categoriesc Greater proportion of children with CNS (39.8%) received SPPC compared to the 
proportions of children with leukaemia (15.6%) and lymphoma (6.6%) (p value 
missing)
Qn-NR 100
Hospice service Klopfenstein et al.55 No details of categories used for 
analysis
Children with solid tumours were more likely to be receiving SPPC (p < 0.01) Qn-NR 50
Hospice service Thienprayoon et al.59 Leukaemia, lymphoma and SCT vs 
brain and solid tumours
Children with leukaemia, lymphoma or SCT were significantly less likely to receive 
SPPC vs children with brain and solid tumours (OR = 0.166, p value missing): 67% 
























Hospice service Mark et al.86 Leukaemia/lymphoma, solid tumours, 
brain tumours
Young adults with leukaemia/lymphoma were less likely to be enrolled in hospice 
care (26.7%) compared to those with solid tumours (66.7%) and brain tumours 
(71.4%) (p value missing)
Qn-NR 25
Hospital team Brock et al.46 Solid, brain, haematologic, 
leukaemia/lymphoma
Diagnosis was not associated with SPPC involvement (p = 0.31) Qn-NR 75
Hospital team Kassam et al.50 Haematologic malignancy Fewer children with haematologic malignancy in the SPPC (14.3%) vs non-SPPC 
group (39.4%) (p = 0.01)b
Qn-NR 0
Hospital team Kaye et al.84 Solid, brain, haematologic Children with a haematologic malignancy (OR = 3.24, p = 0.001) or a brain tumour 
(OR = 2.69, p = 0.003) had higher odds of late SPPC involvement, compared to 
children with a solid tumour
Qn-NRa 100
Hospital team Ullrich et al.61 Solid/brain, haematologic No significant difference between the SPPC and non-SPPC groups (p = 0.0511) Qn-NR 50
Hospital team Widger et al.63 Solid, CNS, haematologic SPPC involvement is significantly less likely for children with haematologic 
malignancies compared to those with solid tumours (OR = 0.3, p < 0.001). No 
difference for children with CNS
Qn-NR 100
Integrated service Golan et al.49 Sarcoma, low/high-grade 
brain tumour, low/high-risk 
neuroblastoma, leukaemia, 
lymphoma, Wilms, haematologic, 
other
Those in the SPPC group (compared to the non-SPPC group) were more likely to 
have high-grade brain tumours, sarcoma or high-risk neuroblastoma (17%, 25% and 
5%, vs 8%, 12% and 1%, respectively) (p value missing). No reported differences for 
other diagnoses
Qn-NR 75
PC consult Keim-Malpass et al.54 Solid, brain, CNS, haematologic Children with solid tumours more likely to receive SPPC (66%) than those with CNS 
(38%) or haematologic malignancies (25%) (p = 0.02)d
Qn-NR 50
PC consult Cuviello et al.78 Leukaemia, sarcoma, NF-1, 
neuroblastoma, glioblastoma, DIPG, 
mantle cell lymphoma, melanoma
No significant differences between the SPPC and non-SPPC groups (p value missing) 
(all patients were enrolled on phase 1 trial)
Qn-NR 0
Disease status (n = 16 
studies)
Hospice service Klopfenstein et al.55 Death caused by progressive disease 
or therapy related
All the children who died from progressive disease were referred to SPPC compared 
to none of the children who died from therapy-related complications (p < 0.001)
Qn-NR 50
Hospital team Ullrich et al.61 Death caused by relapse or 
treatment-related toxicity
Greater proportion of children died from treatment-related toxicity in the SPPC 
(76%) vs non-SPPC (54%) group (p = 0.03)
Qn-NR 50
Hospital team Kassam et al.50 Disease duration (years, diagnosis 
to death)
Children with a shorter disease duration were more likely to be referred to SPPC 
(2.12 years in the SPPC group vs 3.55 years in the non-SPPC group) (p < 0.01)b
Qn-NR 0
PC consult Keim-Malpass et al.54 Disease duration (months, diagnosis 
to death)
Children who received SPPC had a longer disease duration (20 vs 13 months) 
(p = 0.02)d
Qn-NR 50
Hospital team Ullrich et al.61 Disease duration (months, diagnosis 
to death)
There was no difference in disease duration between children receiving and not 
receiving SPPC (p = 0.5)
Qn-NR 50
Hospital team Brock et al.46 Relapsed disease or not No significant difference between the SPPC and non-SPPC groups (p = 0.47) Qn-NR 75
Integrated service Golan et al.49 Disease progressione Disease progression was more common among children receiving SPPC (33% vs 4%) 
(p value missing)
Qn-NR 75
Integrated service Golan et al.49 Poor prognosis vs intent to cure 
(>30% of cure)
Children with an overall poor prognosis were more likely to receive SPPC (91%) 




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
The majority of participants insisted that SPPC should be provided when there 
is no response to curative treatment, and viewed palliative care as non-curative 
care. Despite this, there were uncertainties and disagreements about when to 
initiate SPPC, and nurses in particular believed that these uncertainties led to late 

















care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Physician participants held the view that SPPC is inconsistent with curative intent 
but indicated that early integration of SPPC would benefit patients with a survival 
of <40%–50%. Other participants (nurses, social workers) did not hold this view 
and believed that basing referral on prognosis alone would exclude some patients in 
need: ‘is there another 40% that could benefit from our extra care that would focus 
on their coping ability’, ‘there can be kids with a good prognosis and the family still 
isn’t coping well’. Non-physician participants were more receptive to integrating 




Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
Although few participants (5%) stated that they would not refer any patients within 
the first month of diagnosis, nearly half of the physicians (48%) and social workers 
(45%) stated that they would limit referrals to patients with a poorer prognosis 
(compared to 28% of nurses and 31% of nurse practitioners)
Qn-D 25
Hospice service Fowler et al.65 Paediatric oncologists were asked 
about their referral practices and 
attitudes
Participants most frequently reported referring patients late in the disease course; 
44% at the time of progressive disease, 20% when death was imminent and 26% 
when no additional therapy options were available. Only 2.5% reported referring at 
the time of relapse. 38% of respondents identified ‘extended prognosis’ as a reason 
for not referring children to SPPC.
Qn-D 75
Hospital team Hill et al.83 Paediatric oncology providers’ 
perceptions and uncertainties about 
SPPC
From the results presented, SPPC introduction was associated with a poor prognosis, 
and prognostic uncertainty was a key barrier to SPPC involvement. This was not just 
about whether a child would live or die, but was linked to informational uncertainty 
about diagnosis and treatments, and the uncertainty held by others including 
families, team members and others who were involved in treating a child. These 
uncertainties were believed to delay SPPC involvement until late in a child’s illness, in 
other words when there was greater certainty about their prognosis
QL 100
Palliative 
care team – 
hypothetical
Levine et al.68 Parent and young person dyad 
attitudes towards early integration 
of SPPC
Few parents and young people expressed opposition to early SPPC involvement (6% 
and 2%, respectively). At the same time, just over a quarter of both groups were 
unsure whether they would have accepted a referral at this time. There were varying 
opinions between and within participant groups about the optimal timing for SPPC; 
59% of young people and 50% of parents agreed from the beginning of cancer 
therapy, 32% and 20% throughout a child’s cancer care, 49% and 32% if cancer got 
worse/came back and 42% and 33% at the end of life. Only a small proportion of 
participants (11% of young people, 7% of parents) believed that SPPC would help 
with making initial treatment decisions
Qn-D 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about who should be 
offered SPPC and what the barriers to 
SPPC involvement were
The most common indications for SPPC involvement were situations that occur late 
in the disease trajectory, and only 31% felt that all children with cancer should have 
SPPC. One in five participants defined SPPC as a service offered to patients at the 
‘end of life’ or ‘when death becomes inevitable’, and difficulties with prognostication 
were identified as a barrier to SPPC involvement by 14% of physicians. These 
different understandings about who SPPC is for were identified as the barrier to 
involvement by 46% of participants (56% of nurses compared to 25% of physicians)
Qn-D 50
Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of SPPC 
service and how these may influence 
timing of referral
Participants believed that early involvement of SPPC in the care of children with 
advancing cancer was beneficial, and while no participants explicitly mentioned 
prognosis or disease status as a trigger, all participants described the referral of 
SPPC as being linked to the shift from curative to palliative treatment: ‘in your mind 

























All SPPC models Weaver et al.71 Staff representatives of oncology 
settings were asked about the timing 
and triggers for SPPC introduction 
and barriers to referral (ever a barrier 
and most important barrier)
Several automatic triggers for SPPC referral were related to disease status: diagnosis 
of refractory disease (reported by 32% of participants), diagnosis of recurrent 
disease (31%) and ‘low likelihood’ of anticipated event-free survival above certain 
percent (22%). Only 4% reported that new cancer diagnosis was an automatic 
trigger. 48% of participants reported that the introduction of palliative care 
concepts to families was also ‘prognosis’ specific. Late referrals, which were defined 
as a ‘patient’s disease is too advanced for them to benefit significantly from a 
referral’, were identified as a barrier to referral by 76% of participants and the most 
important barrier by 16% of participants. This was the second most common and 
important barrier
Qn-D 75
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
about their referral practices and 
attitudes
83% of participants reported always or usually referring terminally ill patients, and 
for most participants the life expectancy of patients at the point of referral was 
6 months or less (85%). 65% of participants identified the diagnosis of incurable 
cancer as the ideal time for referral; only 8% identified the time of cancer diagnosis 
regardless of prognosis as an ideal time
Qn-D 100
End-of-life care characteristics (n = 18)
Advance care planning 
(n = 4 studies)
Hospital team Kaye et al.84 Advance directive in place and length 
of time in effect (7 days or less vs 
greater than 7 days before death)
Advance directive not associated with timing SPPC involvement (early vs late) 
(p = 0.14); children with advance directive in place for 7 days or less before death 
had higher odds of late SPPC involvement (OR = 4.81, p < 0.0001)
Qn-NRa 100
Hospice service Brock et al.46 DNR order/POLST in place and 
median days in effect before death
More children in the SPPC (64%) vs non-SPPC (52%) group had DNR order (p = 0.02). 
Orders in place for longer for children who accessed SPPC (30 days) compared to 
those who did not (3 days) (p < 0.0001)
Qn-NR 75
Hospital team Brock et al.46 DNR order/POLST in place and 
median days in effect before death
No significant difference in the proportion of children with a DNR order/POLST 
(p = 0.09); however, orders in place for longer for children who accessed SPPC 
(15 days) vs to those who did not (7 days) (p < 0.05)
Qn-NR 75
Hospice service Klopfenstein et al.55 DNR order in place (for >1 day) and 
length of time in effect before death
DNR orders more likely to occur in children with a hospice referral (p < 0.05). 
Orders were in place for longer for children who accessed SPPC compared to those 
who did not (p < 0.001)
Qn-NR 50
Hospice service Thienprayoon et al.59 DNR status – Yes/No/Withdrawal 
of Care
More children had a DNR order (No) in place in the SPPC (43%) vs non-SPPC (11%) 
group (p < 0.001)
Qn-NR 100
Hospital team Kaye et al.84 Enrolled in hospice at time of death Children receiving hospice care at the time of death had lower odds of late 
SPPC involvement (hospital team) as compared to those not enrolled in hospice 
(OR = 0.29, p < 0.001)
Qn-NRa 100
All SPPC models Weaver et al.71 Staff representatives of oncology 
settings were asked about barriers 
to referral (ever a barrier, most 
important barrier)
Providers varied in terms of whether they introduced palliative care concepts to 
families (e.g. 46% sometimes did this and 32% usually did). There was no significant 
association between the introduction of palliative care concepts and the number 
of SPPC referrals (p = 0.88). However, the odds that palliative care principles were 
introduced to families in settings with automatic triggers for SPPC referral were 
3.41 (1.52–7.69) greater than those in settings which did not use referral triggers 
(p < 0.003)
Qn-D 75
Identifying needs for 




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
Nurse participants felt that children’s needs were not always taken into 
consideration because of late referral practices, although they did identify ‘very poor 
quality of life’ and ‘presence of pain’ as triggering implementation. One participant 
believed that there was not enough need for a specialist service for children with 

















care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Non-physician participants believed that patient needs for palliative care during 
active treatment often go unmet, and that care provided by the oncology team 
did not always attend to symptoms (particularly psychosocial), resulting in a lower 
quality of life for children: ‘why would we wait a month to say, you’re pain and 
symptom management and issues of quality of life are important . . . how can we 
help you?’ Some nurse participants suggested that this was to do with oncologists’ 
different perceptions of children’s needs, and others explained that nurses were 
more likely to ‘hear a lot of the behind the scenes stuff’ (nurse) and were therefore 
more aware of families needs. Some participants believed that having prognostic-




Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
Non-physicians expressed more concern than physicians that quality of life is often 
overlooked in the face of cancer treatment (p < 0.01). Nurses were also more likely 
to believe than physicians that parents avoid addressing symptoms with their child’s 
oncologist for fear of disappointing him/her (p < 0.05). In addition, 74% of social 
worker participants felt that parents worried that talking about end of life would 
lead their oncologist to ‘give up’ on the child (the views among other participant 
groups were divided about this). These findings suggest that parents may avoid 
discussing palliative care needs with their child’s oncologist
Qn-D 25
Hospice service Fowler et al.65 Paediatric oncologists were asked 
about their referral practices
Hospice referrals were more likely among participants who worked in centres with 




care team – 
hypothetical
Levine et al.68 Parent and young person dyad 
attitudes towards early integration 
of SPPC
Young people were more likely than parents to identify when pain or symptom 
management was a problem as the optimal timing for SPPC involvement (49% vs 
34%, p = 0.01). Young people who rated their quality of life as poor or fair were 
more likely to recommend early SPPC involvement (73%) than those who rated their 
quality of life as good (61%), and very good or excellent (52%)
Qn-D 75
Not defined – 
hypothetical
Spencer and Battye76 Staff (mixed group) views about the 
potential role of SPPC for children 
with cancer
Participants believed that the palliative care needs of children with cancer were 
similar to those of children with other life-threatening diseases and could therefore 
be supported by generic services (e.g. children’s community nursing teams). This, 
combined with the small numbers of children with advanced cancer who were 
already being supported by existing services, was not felt to justify a dedicated 
local service. At the same time, participants believed that children’s hospices, which 
were part of existing provision, were not appropriate for the majority of children 
with cancer because of the perception that they primarily provide respite care for 
children with long-term degenerative conditions. They identified specific needs that 
could be met by a children’s hospice, for example, providing an alternative place of 
care for families who did not want to be at home or in hospital during the end of life, 
providing respite at home to support transition to home
QL 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about desire to involve 
SPPC services























Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of SPPC 
service and how these may influence 
timing of referral
Oncologist participants admitted that they did not always have time to meet the 
emotional and psychosocial needs of families, and that the SPPC team addressed 
this unmet need: ‘they have time to sit for an hour, hear the fears, hear the 
problems, partner with that family, cry with that family. I’ve got 17 other patients 
to see . . . I don’t have time . . . and I cannot deliver that to you in an effective way 
. . . that is immensely valuable because they are providing something that I should 
but can’t’. However, non-physician participants believed that oncologists were not 
always able to identify the psychosocial needs of their own patients and sometimes 
needed some encouragement to refer
QL 100
All SPPC models Weaver et al.71 Staff representatives of oncology 
settings were asked about the timing 
and triggers for palliative care 
introduction
56% of participants reported that their sites used automatic ‘triggers’ to prompt 
timely palliative care referrals, several of which were related to specific palliative 
care needs: difficult to manage symptoms or high symptom burden (reported by 
37% of participants), patients needing discussion of advanced directives (24%) 
and difficult social situation or family having difficulty coping (23%). However, 
65% of participants identified a lack of perceived patient need among staff as a 
barrier to SPPC referral; this was identified as the most important barrier by 11% of 
participants
Qn-D 75
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
about referral practices
Participants frequently referred terminally ill patients (prognosis less than 1 year) for 
symptom control (90%) and discharge planning (75%) but less frequently for social 
(23%), psychological (30%) or spiritual concerns (21%). Only 50% of participants 




Hospital team Kaye et al.84 CPR receipt CPR receipt not associated with the timing of SPPC involvement (early vs late) 
(p = 0.26)
Qn-NRa 100
Hospital team Kaye et al.84 ICU admission (numbers) ICU admissions not associated with the timing of SPPC involvement (p > 0.05 for all 
ORs calculated)
Qn-NRa 100
Hospital team Kaye et al.84 Cancer-directed therapy during the 
last month of life
Children who received cancer-directed therapy had higher odds of late SPPC 
involvement compared to those who did not (OR = 5.52, p < 0.0001)
Qn-NRa 100
Hospice service Brock et al.46 Phase 1 trial enrolment More children enrolled in phase 1 trial received SPPC (80% vs 49%) (OR = 4.0, 
p < 0.0001)
Qn-NR 75
Hospice service Levine et al.56 Phase 1 trial enrolment Phase 1 trial enrolment not associated with involvement (p = 0.15) or timing 
(p = 0.23) of SPPC
Qn-NR 75
Hospital team Kaye et al.84 Phase 1 trial enrolment Phase 1 trial enrolment not associated with the timing of SPPC involvement (early 
vs late) (p = 0.11)
Qn-NRa 100
PC consult Ananth et al.43 Phase 1 trial enrolment Children enrolled in phase 1 trial received SPPC later (median 58 days before death) 
than those not enrolled in phase 1 trial (85 days) (p = 0.04). No difference in SPPC 
receipt (p = 0.40)
Qn-NR 100
Hospice service Brock et al.46 SCT recipient Fewer children who had undergone SCT received SPPC (32% vs 60%) (OR = 0.3, 
p < 0.0001)
Qn-NR 75
Hospital team Kassam et al.50 SCT recipient Fewer children who had undergone SCT receive SPPC (27% vs 53%) (p = 0.02)b Qn-NR 0




care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
SPPC was perceived as not consistent with active treatment: ‘The palliative care 
team’s idea of the patient’s quality of life is to not do chemotherapy and to let them 
die of their life-threatening disease’ (oncologist). Oncologists believed that they 
themselves were best placed to manage treatment-related symptoms, but were 
















Hospice service Fowler et al.65 Paediatric oncologists were asked 
about referral practices
57% of respondents identified ‘continued therapy’ as a reason for not referring 
children to SPPC. 45% of SPPC services were reported to accept patients on 
chemotherapy, 68% for patients receiving transfusions and 57% for patients 
receiving total parenteral nutrition (TPN). When asked for suggestions to increase 
hospice referrals, participants believed having more facilities allowing TPN, 
chemotherapy and blood product support would help
Qn-D 75
Palliative 
care team – 
hypothetical
Levine et al.68 Parent and young person dyad 
attitudes towards early integration 
of SPPC
Very few participants (2% of young people and 2% of parents) believed that early 
involvement of SPPC would interfere with their cancer treatment
Qn-D 75
All SPPC models Weaver et al.71 Staff representatives of oncology 
settings were asked about referral 
triggers for SPPC
31% of settings had automatic palliative care referral triggers for children receiving 
SCT. Only 9% of settings had triggers for children referred to a phase 1 trial
Qn-D 75
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
if SPPC accepted children receiving 
certain treatments and about their 
referral practices
The majority of respondents reported that the services available to them accepted 
patients on chemotherapy (64%) and those receiving transfusions (79%). Although 
the majority of participants referred children late on in their disease, only 13% 
reported waiting until after chemotherapy or transfusions had been stopped
Qn-D 100




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
Some participants believed that the primary oncology team could offer all the 
necessary palliative care to children.
QL 100
Palliative 
care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Participants in all provider groups reported concern about overlap in roles 
between the oncology and SPPC team: ‘the definition of what a palliative team’s 
role are exactly what the primary oncologist is doing’ (physician). However, there 
were differences in opinion between groups; oncologists in particular believed 
that patients’ needs for palliative care were already being met and perceived 
treatment-related symptom management and discussions of diagnosis, prognosis 
and treatment options as their responsibility (some perceived a role for SPPC 
in managing disease-related symptoms). However, nurse and social worker 
participants reported that children’s wider psychosocial and quality-of-life needs 




Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
Over half of all participants agreed with the concern that the overlapping role 
between the oncology team and SPPC is a barrier to referral. Nurses were more 
likely to agree to this statement than physicians and social workers (p < 0.05)
Qn-D 25
Hospice service Fowler et al.65 Paediatric oncologists were asked 
how comfortable they were doing 
palliative care
The majority of participants reported being comfortable in managing end-of-life 
pain (86%) and end-of-life psychosocial issues (67%). 43% of respondents identified 
‘access to resources’ as a reason for not referring children to SPPC
Qn-D 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about barriers to 
involving SPPC
Very few participants (<5%) agreed that ‘our team already provides the services 
that SPPC offers’ was a barrier to involvement of SPPC
Qn-D 50
All SPPC models Weaver et al.71 Staff representatives of oncology 
settings were asked about barriers 
to referral (ever a barrier and most 
important barrier)
The perception that paediatric oncology providers already provide adequate 
palliative care was the most commonly reported barrier to SPPC referral (76% of 
participants) and identified as the most important barrier by more participants than 
any other barrier (29%)
Qn-D 75
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
about their attitudes towards SPPC 
referral
68% of participants enjoyed treating patients at the end of life; however, only 37% 
























Acceptability of SPPC (n = 17 studies)




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
Some participants believed that promoting the value of SPPC could help address 
barriers to implementation. However, the uncertainty about when to introduce 
SPPC was linked to not knowing what the ‘added value’ would be. Some participants 
identified the benefits associated with an external palliative care team, which 
included easing the emotional burden on the primary team and offering an 
additional perspective on a child’s needs
QL 100
Palliative 
care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Non-physician participants believed that early involvement of SPPC would ensure a 
focus on addressing quality-of-life issues which they reported as being overlooked 
during active treatment; would address symptoms and suffering better than 
current practice; and lead to enhanced communication and documentation about 
families’ needs and concerns, which some participants believed families did not 
always feel able to discuss with their oncologist. However, the lack of evidence 
about the benefits of early involvement of SPPC was viewed as a barrier to referral, 
and physician participants were not convinced about the added value for patients 
receiving active treatment: ‘I don’t know that the palliative care team has a lot 





Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
The majority of participants believed that early integration of SPPC would provide 
greater attention to symptom management for children with cancer and improve 
interdisciplinary communication. However, there were more mixed views about 
whether early integration of SPPC for all patients diagnosed with cancer would 
decrease patient suffering. For example, 62% of nurses moderately/strongly agreed 
with this statement compared to 48% of physicians and 43% of social workers. All 
participants agreed that evidence about the benefits of early integration was needed
Qn-D 25
Hospital team Hill et al.83 Paediatric oncology providers’ 
perceptions and uncertainties about 
SPPC
Some participants believed that viewing SPPC in terms of the added value for 
families (e.g. ‘I’m offering this family another layer of support’) could help overcome 
barriers to referral, such as concerns about what families might think
QL 100
Palliative 
care team – 
hypothetical
Levine et al.68 Parent and young person dyad 
attitudes towards early integration 
of SPPC
40% of young person participants compared to 18% of parents believed that early 
involvement of SPPC would have been helpful for treating symptoms (p < 0.001). 
However, not all participants (36% of young people and 40% parents) believed that 
early SPPC involvement would have been a positive addition to the overall care 
experience
Qn-D 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about desire to involve 
SPPC services
Nearly all participants (99%) felt that involving SPPC services benefits children and 
their families, through improved symptom management (95%), enhanced patient 
















Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of SPPC 
service and how these may influence 
timing of referral
Participants believed that SPPC added value to what they as oncology providers 
offered (‘it’s value added to my medical care’), particularly bringing expertise in 
symptom and pain management, enabling and supporting home-based care for 
families, having time to provide superior emotional and social support for families 
around the clock and helping families with planning end-of-life care and clarifying 
goals. Participants also valued the communication skills of SPPC team members 
which some participants admitted were superior to their own: ‘This was a family 
that was really doing everything to keep this poor kid alive . . . She just brought 
this mum around in a way that none of us could ever do’ (physician). ‘it’s kind of 
reassurance that we’re gonna take care of you and your child at home and we’re not 
gonna let anything bad happen’ (child life specialist)
Some participants reported that being able to outsource aspects of palliative care 
benefitted them as well as their patients, from knowing that their patients were 
receiving the emotional and social support that they themselves lacked time to 
provide, enabling them to emotionally distance themselves from families if they 
needed to: ‘it doesn’t impact the care that I give them but I feel I emotionally don’t 
let myself get too involved’, and helping them maintain a work–life balance (as a 
result of SPPC becoming the first point of contact around the clock)
QL 100
All SPPC models Weaver et al.71 Staff (mixed group) were asked about 
barriers to referral (ever a barrier 
and most important barrier) from 
predefined list
Not perceiving a benefit from incorporating SPPC was commonly reported as a 
barrier to referral (65%) and identified as the most important barrier by 16% of 
participants. Not being aware of the benefits of SPPC involvement and not being 
aware of the scope of SPPC services were also commonly reported as barriers to 
referral (44% and 55%, respectively). These were identified as the most important 
barrier by 9% and 4% of participants
Qn-D 75




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
Concerns were raised about whether the two teams could successfully work 
together, and some participants were worried about possible interpersonal conflicts
QL 100
Palliative 
care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Some participants believed that having another team addressing aspects of PC 
might negatively affect their relationship with families. Physicians in particular 
indicated that outsourcing PC to another team could ‘make the oncologist look bad’. 
Physicians also expressed concerns about sharing responsibility for their children 
with a new team: ‘overlapping discussions will decrease trust’ (oncologist)
QL 100
Palliative 
care team – 
hypothetical
Levine et al.68 Parent and young person dyad 
attitudes towards early integration 
of SPPC
Very few participants (5% of young people and 4% of parents) believed that early 
involvement of SPPC would interfere with their relationship with their oncologist
Qn-D 75
Not defined – 
hypothetical
Spencer and Battye76 Staff (mixed group) views about the 
potential role of SPPC for children 
with cancer
Participants expressed concerns that SPPC involvement for children who became 
palliative would undermine continuity of care, which was identified as the best 
model for supporting children with cancer
QL 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked barriers to involving 
SPPC
Very few participants (<5%) agreed that the time it takes to involve a new team 

























Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of SPPC 
service and how these may influence 
timing of referral
Some participants believed that SPPC referral could alienate families with whom 
they had a good relationship, and also negatively affect relationships with families 
which were already strained: ‘that family where your relationship is tenuous and 
this offer is so upsetting that it just impairs your relationship with them’. This was 
reported to delay timely introduction of SPPC for families
QL 100
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
about their attitudes towards SPPC 
referral
Only 17% of participants indicated that involving SPPC would add too many care 
providers and very few (2%) believed that referring to SPPC is an abandonment of 
patients
Qn-D 100




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
Some participants acknowledged that they have difficulty accepting a child’s change 
in prognosis and described sometimes being too emotionally involved to start SPPC 




care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Oncologists’ emotions about their own patients (e.g. their hope for cure even when 
prognosis was poor, their fear of failure and responsibility for saving their patients) 
were reported to influence patient care and act as a barrier to SPPC referral: ‘part 
of me that really wants to hold on and keep pressing the family to go for curative 
intent and it’s maybe not the rational thing to do’ (oncologist), ‘we try to put a 




Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
Physician participants slightly agreed that the emotional relationship between 
physician and family was reported to influence what treatment options are offered, 
and moderately agreed that this influences how options are conveyed to families. 
Nurses agreed to a lesser extent (p < 0.01)
Qn-D 25
Hospital team Hill et al.83 Paediatric oncology providers’ 
perceptions and uncertainties about 
SPPC
Some participants acknowledged sometimes waiting too long before consulting 
the SPPC team because they were emotionally involved with the family. As one 
participant explained: ‘There are two patients I can think of . . . I would go batshit 
crazy trying anything on the planet to try and save the lives of those two children 
. . . I would need someone else to step in and have that conversation because I 
couldn’t do it’. Accepting a child’s change in prognosis could also generate feelings 
of failure, and worries about what families would think of them and how they would 
react, both of which impacted on referring children to SPPC. Some participants also 
worried about how this discussion would impact on their relationship with families. 
Introduction of SPPC was perceived as ‘emotionally risk’
QL 100
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about barriers to SPPC 
involvement
Just over a third of the participants identified discomfort discussing SPPC with 
families as a barrier to involvement. More nurses (47%) than physicians (13%) and 
advanced practice professionals (e.g. nurse practitioners, physician assistants) (26%) 
















Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of SPPC 
service and how these may influence 
timing of referral
Some delays in referring to SPPC were reported to be about professionals not being 
ready rather than families: ‘We say it is the family [who isn’t ready for SPPC] but 
it’s a little bit us. We say “they can’t hear it. They’re not ready”. Which sometimes 
means “I can’t hear it. I’m not ready”’ (physician). Introducing the service to 
families was described as difficult and emotional work: ‘If you’re going to sit with 
a family and discuss the merits, the benefits, why we think it’s important, you have 
to first explain where we’re at. Why am I telling you this today? So it is recapping 
everything, where we’ve been, what we’re going through, why I’m nervous today, 
why I think we need to get another team involved’ (physician), ‘you know this is 
his second relapse. But his family is like in a totally different direction. . .And this is 
my primary patient, we email all the time and they tell me they love me and we’re 
like, I’m like part of the family. But I still haven’t gone there (SPPC referral) so I feel 
responsible for that too . . . it is hard to not alienate them, to be honest with them 
without alienating them’ (physician), . . . ‘I can only imagine it is very hard to shift 
the conversation from ‘my child is dying’ to ‘how can I make life the best for the time 
remaining’. That cannot happen in one conversation’ (psychologist)
QL 100
Clinical ownership (n = 4 
studies)
Palliative 
care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Nurse participants identified the physicians’ need to control aspects of patient care 
and maintain ownership of their patients as a barrier to SPPC referral. ‘I don’t know 





Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
Around half of the participants believed that paediatric oncologists’ need to control 
all aspects of patient care was a barrier to SPPC. Non-physicians (56%) were more 
likely to report this as a barrier than physicians (45%) (p < 0.01)
Qn-D 25
Hospital team Hill et al.83 Paediatric oncology providers’ 
perceptions and uncertainties about 
SPPC
Certain physicians were known to be more or less receptive to SPPC. This varying 
acceptability of SPPC among clinicians led to uncertainty about how, when and 
whether to suggest a referral for a child, and some participants described the 
practice of keeping quiet until the primary oncologist or the service treating a child 
at the time made a decision, even when they thought their opinion was wrong
QL 100
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about utilisation of SPPC 
services
Participants reported no pressure from their institution or colleagues about whether 
or not to involve SPPC
Qn-D 50
Family readiness (n = 4 
studies)
Palliative 
care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Nearly all participants expressed concern that introducing SPPC early (around 
diagnosis) could lead to additional parental burden. Physician participants in 
particular believed that families may not be ready for SPPC involvement during the 
diagnostic period. However, some non-physician participants expressed that the 
anxiety caused by early integration would be far less than the anxiety experienced 
if SPPC was not introduced until relapse/disease progression. As one nurse pointed 


























Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
Participants were divided about whether parents were ready for SPPC around 
diagnosis, with just under half agreeing that early involvement would increase 
parental anxiety. However, participants did agree that introducing SPPC would not 
create an additional burden for parents overall, and that the potential benefits 
would outweigh the risks. They also agreed that early integration as the standard of 
care would reduce anxiety associated with SPPC
Qn-D 25
Hospital team Hill et al.83 Paediatric oncology providers’ 
perceptions and uncertainties about 
SPPC
Uncertainty about whether a family was ready to hear about SPPC and accept a 
change in their child’s diagnosis was identified as a key barrier to referral, and 
some participants worried that having the conversation too early would impact on 
their relationship with the family. Some participants were also concerned about 
advocating too much for SPPC as they did not want families to stop treatments 
before they were ready. Uncertainty about what information a family had already 
received, that is, how ready they were to be introduced to SPPC, was also a barrier 
to referral.
QL 100
Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of SPPC 
service and how these may influence 
timing of referral
Most participants suggested that the reason SPPC is not consulted earlier is because 
they perceive that families are not emotionally ready for them: ‘it’s knowing that if 
I call at a certain point, the family is gonna reject [SPPC]’ (physician), ‘you fear that 
you would alienate the family and especially a family who is very much in denial’ 
(physician). Some participants also believed that in these cases there could be 
negative consequences: ‘they just feel like the child is dead. They don’t understand 
that there is still time’ (physician)
QL 100




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
Family reluctance was identified as a barrier by healthcare staff participants, who 
believed that they associated SPPC with giving up
QL 100
Hospice service Fowler et al.65 Paediatric oncologists asked about 
their referral practices
24% of paediatric oncologist respondents identified ‘family refusal’ as a reason for 
not referring children to SPPC
Qn-D 75
Palliative 
care team – 
hypothetical
Levine et al.68 Parent and young person dyad 
attitudes towards early integration 
of SPPC
Only 1% of young people and parent participants believed that SPPC should not be 
involved in a child’s cancer treatment (regardless of timing)
Qn-D 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about barriers to SPPC 
involvement
38% of participants identified family resistance as a barrier to SPPC involvement Qn-D 50
All SPPC models Weaver et al.71 Staff (mixed group) were asked about 
barriers to referral (ever a barrier 
and most important barrier) from 
predefined list
54% of staff participants identified parental negative perception of palliative care as 
a barrier to SPPC referral. This was the most important barrier for 9% of participants. 
In contrast, only 28% of participants identified patient (child/young person) negative 
perception as a barrier, and no one rated this as the most important barrier
Qn-D 75
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
about their attitudes towards SPPC 
referral
60% of paediatric oncologist respondents believed that their patients had negative 







Zernikow et al.90 Cohort years: 2000, 2005 and 2010 Proportion of children receiving SPPC significantly increased from 34.8% in 2000 
to 64.6% in 2005, but the difference between 2005 and 2010 (60.7%) was not 

















Hospice service Brock et al.46 Time periods (time of death): 
2002–2004, 2005–2007, 2008–2010 
and 2011–2014
No significant difference in hospice enrolments over time (p = 0.55) Qn-NR 75
Hospice service Fraser et al.23 Time period (year of death and 
referral): 1990–1993, 1994–1997, 
1998–2001 and 2002–2005
No significant difference in the number of referrals between time periods (p = 0.43) Qn-NR 100
Hospital team Brock et al.46 Time periods (time of death): 
2002–2004, 2005–2007, 2008–2010 
and 2011–2014
Greater percentage of children accessed SPPC in recent quartiles (p = 0.04): 27% of 
children in 2011–2014 compared to <20% in other periods
Qn-NR 75
Hospital team Lafond et al.67 Referral rates to SPPC and clinician 
attitudes about referring to SPPC
All 12 eligible children were referred: oncology providers reporting being 
comfortable or very comfortable referring families to SPPC and were very likely to 
recommend the service to others
Qn-D 100
Hospital team Lafond et al.67 Uptake of SPPC and families’ 
attitudes about accessing SPPC
All 12 families referred were enrolled and received SPPC: parents indicated that it 
was very important to offer SPPC and were very likely to recommend SPPC to others
Qn-D 100
Hospital team Mahmood et al.69 Whether primary oncologist agreed 
to SPPC
No oncologist asked for the initial palliative care consultation with families to be 
deferred
Qn-D 100
Hospital team Mahmood et al.69 Enrolment and uptake of SPPC 
(measured using the initial palliative 
care consultation)
Anticipated 75% enrolment among families; achieved 80% (20 of 25) enrolment and 
all 20 families received the initial palliative care consult
Qn-D 100
Hospital team Ullrich et al.61 Palliative care consultation rates 
over time
Rates of palliative care consultation increased over the study period from 5 over the 
first 3 years to 17 over the last 3 years (p value missing)
Qn-NR 50
Hospital team Widger et al.63 Time periods (time of death): early 
2000–2004, mid-2005–2008 and late 
2009–2012
Children were more likely to access SPPC later in the study period compared with 
earlier (OR = 43, p = 0.01): referrals up from 8.2% of children in 2000–2004 to 84.3% 
in 2009–2012
Qn-NR 100
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about utilisation of SPPC 
services
Nearly all participants (95%) reported that SPPC services were available at their 
facility, but 56% stated that they never or rarely involved SPPC for their paediatric 
patients with cancer. Services were utilised more by staff working in children’s 




Hospice service Fowler et al.65 Paediatric oncologists were asked if 
they had access to SPPC
86% reported having access to a local hospice facility, 75% to a hospice palliative 
care programme, but only 27% to an inpatient hospice facility. Hospice referrals 
were predicted by the availability of a hospice facility (OR = 5.6 (2.4–13.3), 
p < 0.001)
Qn-D 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about barriers to SPPC 
involvement
Although availability of SPPC services was high (95%), perceptions about available 
resources and access to SPPC was identified as a barrier by 17% of participants. Very 
few participants (around 5%) identified lack of community resources as a barrier. 
Staff from children’s hospitals were less likely to identify these as barriers compared 
























All SPPC models Weaver et al.71 Staff (mixed group) were asked about 
access to SPPC and barriers to referral 
(ever a barrier and most important 
barrier) from predefined list
75% of participants reported having access to an SPPC service where they worked, 
15% to an SPPC contact person but not a service and 10% had no SPPC services 
available to them (3% of these utilised adult providers). Views about whether 
capacity met demand varied and there was no significant association between 
perceived capacity and the number of SPPC referrals (p = 0.97). Lack of palliative 
care availability was only identified as a barrier by 1.5% of participants and was not 
rated as the most important barrier by anyone. However, a greater proportion of 
participants (36%) identified inadequate palliative care staffing as a barrier, and this 
was identified as the most important barrier by 6% of participants
Qn-D 75
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
if they had access to different types 
of SPPC
96% of respondents reported that they had access to hospital-based SPPC (although 
availability of other types of SPPC was much lower) and 73% agreed or strongly 
agreed that they were satisfied with availability of SPPC
Qn-D 100




De Clercq et al.79 Paediatric oncology providers’ 
perceptions about obstacles to SPPC 
implementation
The association of SPPC with ‘death and dying’, ‘loss of hope’ and ‘giving up’ was 
identified by many participants as a barrier to implementation. One participant 
described the term ‘palliative’ as the biggest enemy when addressing families, as 
one participant explained, ‘we are afraid of pronouncing the word and at the same 
time we do not know how to tell it differently’. Some participants felt that palliative 
care was also associated with the elderly and therefore difficult to reconcile with 
children’s lives. The different meaning of palliative care in other cultures was also 
identified as a potential barrier. Standardising the introduction of SPPC earlier in the 
care pathway, rebranding the name of SPPC and improving public perceptions and 
promoting its value were all identified as potential solutions
QL 100
Palliative 
care team – 
hypothetical
Dalberg et al.75 Paediatric oncology providers’ 
perceptions of early integration of 
SPPC service (around diagnosis)
Nearly all participants believed that early referral (around diagnosis) would lead to 
additional parental anxiety because of the association between the term ‘palliative 
care’ and end of life, although one nurse pointed out that ‘a very small percentage 
of people even know what that word means’. Changing the service name to 
‘supportive care team’ or ‘quality of life team’ was identified as a possible solution. 
Early integration of SPPC as the standard of care, which could focus on educating 
families about the role and benefit of SPPC, was also identified as something which 
might help address concerns about what a referral symbolises: ‘if it’s standard of 
care, it’s very simple; it’s the standard of care rather than meeting the death squad’, 





Dalberg et al.81 Paediatric oncology providers’ 
perceptions of the barriers and 
facilitators to early integration of 
SPPC
Public and provider perceptions that palliative care is synonymous with end of life 
were identified as a barrier to early integration of SPPC. Interestingly, staff were 
more likely to report these beliefs to exist in professional groups other than their 
own (e.g. 73% of physicians believed that nurses associated palliative care with end 
of life compared to 50% of nurses). All providers agreed that changing the name of 
SPPC would help, along with education for parents and healthcare providers
Qn-D 25
Hospital team Hill et al.83 Paediatric oncology providers’ 
perceptions and uncertainties about 
SPPC
Participants were worried that SPPC introduction would be associated with the loss 
of hope, and the team giving up on their child, because of its association with death. 
Because of the late involvement of SPPC, the conversation about SPPC involvement 
was also associated with telling a family bad news about their child’s prognosis and 
therefore generated uncertainties about how a family would react. One participant 

















care team – 
hypothetical
Levine et al.68 Parent and young person dyad 
attitudes towards early integration 
of SPPC
The majority of parent (62%) and young person (98%) participants reported that 
they had not heard of the term palliative care, and of those familiar with it none 
reported a negative attitude. When learning that SPPC provides end-of-life care in 
addition to symptom management and quality-of-life directed care, 16% of young 
people and 15% of parents reported that they would have been less willing to meet 
with the team around diagnosis; however, 26% of young people and 18% of parents 
reported a greater willingness. Only 2% of young people and 8% of parents believed 
that SPPC referral would be associated with the loss of hope for a cure
Qn-D 75
Not defined – 
hypothetical
Spencer and Battye76 Staff (mixed group) views about the 
potential role of SPPC for children 
with cancer
Participants believed that a separate SPPC team would be seen as ‘death nurses’ QL 75
All SPPC models Spruit et al.89 Paediatric oncology providers (mixed 
group) asked about barriers to 
involving SPPC services.
The belief that SPPC involvement would be misinterpreted as ‘giving up’ was the 
most commonly cited barrier for oncology providers (49% of participants) when 
deciding whether to involve SPPC. In addition, 29% of participants believed that SPPC 
involvement led to loss of hope for families
Qn-D 50
Hospital team Szymczak et al.77 Paediatric oncology providers were 
asked about their perceptions of SPPC 
service and how these may influence 
timing of referral
Numerous participants explained that they believed families hear ‘palliative’ as 
‘death’ and reported that parents of children who had been cared for at the hospital 
for a long time referred to the SPPC team as ‘the death team’. Many participants 
believed that the term palliative care acted as a barrier to introducing the service: 
‘when a regular family hears the word palliative they just hear their kid is dying. 
That’s it. They can’t focus on anything else’ (psychologist). For some, palliative care 
was also associated with the term ‘hospice’ for families, which was described as 
another term meaning death: ‘I just think the association of the word palliative, 
particularly with families who’ve had experience, maybe like grandma or grandpa, 
somebody went home on hospice – I think that is an immediate trigger, just the 
word’ (social worker)
QL 100
All SPPC models Wentlandt et al.72 Paediatric oncologists were asked 
about their attitudes towards SPPC 
referral
58% of participants indicated that they would refer earlier to SPPC if it were 
renamed ‘supportive care’, although only 6% reported feeling uncomfortable 
referring children who were not terminal
Qn-D 100
Results in Italics indicate studies that sought the views of families or healthcare staff.
SPPC: specialist paediatric palliative care; Qn-NR: quantitative non-randomised; OR: odds ratio; SCT: stem cell transplant; Qn-D: quantitative descriptive; ICCC: International Classification of Childhood Cancer; CNS: central nervous sys-
tem; NF-1: neurofibromatosis type 1; DIPG: diffuse intrinsic pontine glioma; QL: qualitative; DNR: do-not-resuscitate; POLST: Physician Order for Life-Sustaining Treatment; CPR: cardiopulmonary resuscitation; ICU: intensive care unit.
aStudy comparing late versus early SPPC.
bIn the multivariable analysis, the presence of a hematologic malignancy was the only factor that remained significant; SCT, disease duration and age did not.
cICCC categories include leukaemia, lymphoma, CNS, neuroblastoma, retinoblastoma, renal, hepatic, bone, soft tissue, germ cell, other epithelial and other.
dThe no-SPPC group included children who first received SPPC on the day of death.
eProgression was determined by whether children moved into a different medical category using four categories: IC – intent to cure, ICP – intent to cure palliative, NC – non-curable and TC – terminal care.
Table 4. (Continued)
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care planning (e.g. documented advance directives or 
DNRs, hospice referrals) was associated with an increased 
likelihood of specialist involvement, or earlier compared 
to late involvement.46,53,55,59 Provision of palliative care by 
the oncology team (we already do palliative care) was 
also reported by oncology staff to influence referral prac-
tices65,71,72,75,79 and to impede oncologists’ abilities and 
willingness to identify needs for specialist input in their 
patients and practice, something that was reported to 
encourage referrals.65,71,72,75–77,79,89 Similarly, young peo-
ple were more likely to accept specialist input if they had 
specific unmet needs, for example, pain and poor quality 
of life,68 although staff in one study were concerned that 
parents might not discuss their child’s palliative care 
needs during active treatment.81
There was conflicting evidence about whether treat-
ment intensity (e.g. phase 1 trial enrolment) influenced 
access to specialist palliative care,43,46,50,53,56,61 and this 
mirrored varying beliefs among oncology staff and fami-
lies about whether children receiving active treatments 
should or could be referred.65,68,71,72,75
Acceptability of specialist paediatric 
palliative care
Staff acceptability of specialist palliative care was reported 
to influence access in 16 studies. Family acceptability was 
identified in 13, although families’ views were sought in 
only three of these.67–69 Eight studies measured interven-
tion uptake to explore acceptability.23,46,61,63,67,69,89,90 These 
reported varying rates of referral and uptake of specialist 
palliative care, but provided evidence of increasing 
involvement over time.
Staff uncertainties about the benefits of specialist 
palliative care, and about how a specialist service differs 
from care provided within oncology (the added value of 
specialist paediatric palliative care), were identified as key 
barriers to referral.68,75–77,79,81,83,89 Concerns that bringing 
in a new team could undermine continuity of care and 
impact on relationships with families were also reported 
to influence referral practices,68,72,75–77,79,89 as were per-
ceptions about availability and capacity of specialist palli-
ative care services (perceived availability).65,71,72
Staff in eight studies identified the association of palli-
ative care with end of life (what specialist paediatric pal-
liative care symbolises) as a barrier to access.72,75–77,79,81,83,89 
A clinician’s emotion about a family and their readiness to 
accept a child’s prognosis and discuss this were identified 
as additional challenges,75,77,79,81,83,89 and contributed to 
what was described as the emotional labour associated 
with introducing a service which staff participants referred 
to as ‘death nurses’,76 ‘the death team’77 and ‘the death 
squad’.75 A perception that oncologists need to control 
patient care (‘clinical ownership’) was identified as a fur-
ther barrier to specialist palliative care referral and could 
deter others involved in a child’s care from recommending 
this for a family.75,81,83,89
Oncology staff reported that family readiness75,77,81,83 
and family resistance65,71,72,79,89 could affect access, 
although views on this varied. For example, 60% of paedi-
atric oncologist respondents in one survey believed that 
their patients had negative perceptions of specialist palli-
ative care, but very few (4%) reported that patients 
refused a referral.72 In another study, only 38% of staff 
participants identified family resistance as a barrier,89 and 
the study that explored young people and parents’ atti-
tudes found mainly positive views, and very few partici-
pants (2% and 8%, respectively) believed that referral was 
associated with the loss of hope for a cure,68 which was a 
fear commonly reported by staff.72,75–77,79,83,89
Discussion
Main findings of the review
This systematic review found evidence that children and 
young people with cancer who receive specialist paediatric 
palliative care are more likely to be engaged in advance 
care planning, receive less intensive care at the end of life 
and are less likely to die in hospital, compared to those 
who do not receive this. Some of the included studies also 
indicate that these differences may be more marked when 
children receive specialist input for a longer duration 
before they die. The review did not find that receipt of spe-
cialist palliative care is associated with improved quality of 
life or symptom control; however, no conclusions can be 
drawn because of the significant methodological limita-
tions of the seven studies investigating this.48,57,58,64,66,67 
Importantly, only one study sought young people’s views 
about the impact of these specialist services across the 28 
studies which examined this, and this was a feasibility 
study with no comparator group.67
The review also found that the type of cancer and 
whether or not paediatric oncology teams themselves 
engage in palliative care practices may affect access to 
specialist palliative care services. Thus, studies reported 
fewer children with haematological malignancies receiv-
ing specialist palliative care, and involvement more likely 
where the oncology team were proactively addressing 
palliative care needs (e.g. evidence of advance care plan-
ning). There was no indication from the studies included 
about why children with certain cancers are less likely to 
receive specialist palliative care, and a recent review of 
barriers to access did not explore this.31 Evidence from 
adult cancer91 indicates that the remitting and relapsing 
trajectories of haematological malignancies, a more 
aggressive approach to treatment and greater difficulties 
predicting prognosis may contribute to the observed 
inequity of specialist palliative care involvement.92 
Evidence from our review regarding clinician uncertainty 
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about when to involve specialist palliative care, combined 
with the commonly reported practice of referring children 
with a poor prognosis,27 suggests this might be the case.
Clinicians’ views regarding the need for specialist palli-
ative care input for their patients and their acceptability 
of specialist palliative care services were also consistently 
reported as affecting referral practices. More specifically, 
views on how these specialist services differ to palliative 
care provided by the oncology team, perceived drawbacks 
associated with involving a new team, readiness to accept 
a change in prognosis and the negative connotations 
associated with the term ‘palliative care’ were identified 
as barriers to referral. Concerns among clinicians about 
how families might react to the offer of a referral was a 
common theme in several studies, and although the study 
that explored young people and parents’ views runs coun-
ter to this, wider work on this issue reports mixed opin-
ions among young people93,94 and parents73,74 about 
palliative care and how this should be introduced.95,96
Strengths and limitations
This review is the first to systematically synthesise the 
available evidence about specialist paediatric palliative 
care for children and young people with cancer. Strengths 
of the review include a published protocol, robust search, 
independent screening and data extraction by two 
reviewers, and the use of appropriate mixed-methods 
techniques to synthesise the results. There are, however, 
limitations in the conclusions which can be drawn from 
this review due to the heterogeneity of study populations 
and interventions. This, and the substantial risk of potential 
bias identified in some of the studies and inconsistency of 
measurement across studies, meant it was inappropriate 
to aggregate the results statistically, or to compare results 
between the different approaches to providing specialist 
palliative care. In addition, the descriptions of specialist 
services and the palliative care provided by oncology 
teams were typically very poor, making interpretation of 
the differences between these challenging.
What this review adds
Our finding that end-of-life care is different for those who 
receive specialist paediatric palliative care compared to 
those who do not broadly aligns with three recent reviews 
about children with all life-limiting conditions.19,28,29 Two 
of these reviews19,29 concluded that specialist interven-
tion appears to offer benefit in terms of improved quality 
of life. By focusing only on children and young people with 
cancer, our review highlights the lack of robust evidence 
pertaining to both quality of life and symptom burden in 
this population. Although the broader literature implies 
that other differences we observed, such as reduced hos-
pital stays and more advance care planning, are indicative 
of better care,63 there is no evidence that these changes in 
the delivery of care reflect family preferences,48,51,57 or 
lead to reduced symptom burden, which studies continue 
to show is significant for children with cancer.5,90,97
The integration of findings from evaluation studies and 
those which have explored factors affecting access tells us 
that while end-of-life care may be different for children 
who receive specialist palliative care, children who receive 
this are also different to those who do not, particularly in 
terms of their disease profile and care processes. Synthesis 
of the qualitative studies go some way to explaining these 
differences, highlighting in particular the central role of cli-
nicians’ emotions, beliefs and attitudes in shaping referral 
practices, and the ongoing uncertainty about when to initi-
ate palliative care and whether this should be provided by 
a specialist service or the oncology team. It also reveals 
that, in practice, decisions and discussions about no longer 
pursuing curative treatments and introducing specialist 
palliative care go hand in hand, and that families who are 
comfortable discussing an uncertain future or families 
cared for by clinicians who have this confidence may be 
more likely to receive specialist palliative care.75,77,83
Interventions that support clinicians to initiate pallia-
tive care with families and improve clinical acceptability 
of specialist palliative care services therefore offer the 
potential to address these key barriers to access.82,98 
Although there are various initiatives to support the deliv-
ery of palliative care within oncology services (e.g. pallia-
tive care training,99,100 communication tools,101,102 early 
integration models26,67,69), we know very little about 
whether these are being implemented in practice and 
how they might influence referral to specialist palliative 
care. There is also little available evidence about whether 
families play an active role in the initiation of palliative 
care, or whether clinicians’ concerns about how families 
will respond to a referral are warranted.68
Future research should therefore investigate the effec-
tiveness, delivery and acceptability of the different mod-
els of delivering palliative care for children and young 
people with cancer, particularly outside of North America. 
Future research also needs to examine factors affecting 
uptake from families’ perspectives and to explore the role 
of socioeconomic factors. This conclusion is supported by 
the recent priority setting partnership results for teenag-
ers and young adults with cancer,103 which includes how 
best to support young people who have incurable cancer 
and their families. In order to undertake this research, we 
must first determine what outcomes are the most impor-
tant to measure and develop appropriate tools to meas-
ure them.104–107 Development of a core outcome set 
would meet this requirement.108 This too will need to 
include the views of children and young people and their 
families, particularly if we are to address the methodo-
logical challenges that continue to affect the quality of 
research in this area, and the lack of evidence about 
whether specialist paediatric palliative care improves 
quality of life for children and their families.
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